Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download - Evolving Views in Uropathology
Document related concepts
no text concepts found
Transcript
Massimo Loda Curriculum Vitae Date Prepared: September 17, 2015 Name: Massimo Loda, M.D. Office Address: Departments of Pathology and Medical Oncology 450 Brookline Avenue, D 1536 Boston, MA 02115-5450 Home Address: 9 Coolidge Road, Belmont, MA 02478 Work Phone: 617-632-4001 Work Email: [email protected] Work FAX: 617-632-4005 Work Website: www.lodalab.org http://www.dfci-cmop.org Place of Birth: Vigevano (PV), Italy November 19, 1955 Education 1974-76 1980 Pre-clinical M.D., cum laude Postdoctoral Training 07/80-06/85 Resident 07/85-06/86 Resident 07/86-06/88 07/88-06/89 Resident Fellow Medicine & Surgery Emergency Surgery General Surgery Anatomic Pathology Anatomic and Molecular Pathology University of the Witwatersrand, Johannesburg, South Africa University of Milan Milan, Italy Ospedale Policlinico, University of Milan, Italy Deaconess Hospital, Harvard Medical School, Boston, MA Deaconess Hospital, Harvard Medical School New England Medical Center, Tuft University, Boston, MA Licensure and Certification 1980 198119851985 1986 1988 1989 State licensure examination, Italy ECFMG examination FMGEMS examination Boards in Emergency Surgery, Italy FLEX Examination Massachusetts Medical License American Board of Anatomic Pathology (re-certification 2014) Loda - CV Faculty Academic Appointments 1984-1985 1988-1989 1997-1998 Assistant Research Professor Instructor Lecturer Surgery Pathology Pathology 1992-1994 1994-1999 1999-2006 2006 2007 Instructor Assistant Professor Associate Professor Professor Associate Member Pathology Pathology Pathology Pathology 2011-2017 Visiting Professor in Molecular Oncology Division of Cancer Studies Boston University, Boston, MA Tufts University, Boston MA Residency Training Programs in Anatomic Pathology and Medical Oncology, University of Bologna, Bologna, Italy Harvard Medical School, Boston, MA Harvard Medical School Harvard Medical School Harvard Medical School Broad Institute of Harvard and MIT, Cambridge, MA King’s College London School of Medicine, London, UK 2015 – Visiting Professor Pathology Course Universita’ Vita-Salute, Milan, Italy Appointments at Hospitals/Affiliated Institutions 05/90-03/92 04/92-03/96 Pathologist and Director Staff Pathologist and Director 04/92-06/96 07/96-06/98 07/98-09/05 Director Medical Director Director 07/98-present Staff Pathologist 1/06-present Director 07/07-06/10 Director 04/07-present Member Molecular Pathology Laboratory Immunohistochemistry Laboratory and Molecular Pathology Laboratory Tissue Bank Molecular Diagnostic Laboratory Molecular In Situ hybridization and Prostate Human Pathology Cores Center for Molecular Oncologic Pathology (CMOP) Genito-urinary Pathology Service, Department of Pathology Center for Cancer Genome Discovery (CCGD) Institute of Anatomic Pathology, Ospedale Bellaria, Bologna, Italy New England Deaconess Hospital, Boston, MA New England Deaconess Hospital Beth Israel Deaconess Medical Center Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA Brigham & Women’s Hospital, Boston, MA Dana-Farber Cancer Institute/Brigham & Women’s Hospital, Boston, MA Brigham & Women’s Hospital, Boston, MA Dana-Farber Cancer Institute, Boston, MA Other Professional Positions 1992-1998 1996-1998 1997-1999 1999-2005 1999 1999-2002 2000-2002 2001-2003 2001-2010 2003-2009 Staff Pathologist (Consultant) Consultant Consultant Member, Scientific Advisory Board Member, External Advisory Board for Grant Proposal, “Prospective studies of diet and cancer in men and women” Consultant Consultant Member of the Scientific Advisory Board Consultant Member, External Advisory Board 2 New England Baptist Hospital, Boston, MA Mitotix, Inc., Cambridge, MA Oncor, Inc., Gaithersburg, M.D. BIOGENIX, Inc., San Ramon, CA Harvard School of Public Health, Boston, MA GPC, Biotech, Inc., Cambridge, MA Vertex Pharmaceuticals, Cambridge, MA Impath, Inc., New York, NY Novartis Pharmaceuticals, Basel, Switzerland Program Project Grant “Biology of the Prostate Cancer Prevention Trial” (PI Scott Lippman, M.D.) Loda - CV 2004 2005-present Member, External Advisory Board, Genitourinary SPORE Grant, PI: John Stein & Richard Cote Member, External Advisory Board 2006-present 2007 Member, Scientific Advisory Board Member, Scientific Advisory Board 2007 Member, External Advisory Board 2007-2009 2007-present 2007-2009 2008-present 2008-present 2009 2010-present 2010-present Member, Scientific Advisory Board Member, Scientific Advisory Board Consultant Member, External Advisory Board Consultant Consultant Member, Scientific Advisory Board Co-Chair, The Cancer Genome Atlas (TCGA) Prostate Disease Working Group Member, Integration Panel, Prostate Cancer Research Program (PCRP), Congressionally Directed Medical Research Program Member, Interrnal Advisory Board 2010-2012 2010-2011 University of Southern California Pacific NW Prostate Cancer SPORE, Fred Hutchinson Cancer Center, Seattle, WA Cell Signaling Technology, Danvers, MA Champalimaud Foundation, Lisbon, Portugal, Cold Spring Harbor Laboratory, The Robert Wood Johnson Medical School, New Jersey Prostate Cancer SPORE The DNA Repair Company (DNAR), Boston, MA Mitra Life Sciences, Inc., Bangalore, India Merck Pharmaceuticals, Boston, MA UCLA Prostate Cancer SPORE, Los Angeles, CA Infinity Pharmaceuticals, Cambridge, MA Myriad Genetics, Salt Lake City, UT Metamark, Cambridge, MA National Cancer Institute, National Institutes of Health, Bethesda, MD Department of Defense 2010-2011 Member, Tissue-based Biomarker Assays Subcommittee (TBBA) Beth Israel Deaconess Medical Center: Kidney Cancer SPORE, Boston, MA National Cancer Institute, National Institutes of Health 2011-2016 Member, Scientific Advisory Board, 5-year term Pezcoller Symposium, Trento Italy 2011-present Scientific Advisory Board for the Prostate Cancer Research Consortiums programme grant to the Irish Cancer Society Dublin, Ireland 2011-present Member, Ad Hoc Search Committee for Pathology and Genetics Professor Recruitment Harvard Medical School Boston, MA 2014 – Member, New York Academy of Sciences 2014- Member, External Advisory Board UCSF Prostate Cancer SPORE, San Francisco, CA 2014 – Member International Society of Urological Pathology 2015-2019 Member, Tumor Cell Biology Study Section, NCI 2015 Member, Association of American Physicians Major Administrative Leadership Positions Local 1992-1996 1996-1998 2007-2010 Regional 1998-2005 Director, Diagnostic Immunohistochemistry Laboratory and Diagnostic Molecular Pathology Laboratory Director, Diagnostic Molecular Pathology Laboratory Director, Genito-Urinary Pathology Service Deaconess Hospital, Boston, MA Director, in situ Hybridization and Prostate Pathology Core Facilities Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA 3 Beth Israel Deaconess Medical Center Brigham & Women’s Hospital Loda - CV 2006-present Director, Center for Molecular Oncologic Pathology (CMOP) Dana-Farber Cancer Institute/Brigham & Women’s Hospital, Boston, MA Member, Radiation Safety Committee New England Deaconess Hospital 1994-1998 Institutional Review Board (IRB) Member, Human Genetic Research IRB Subcommittee New England Deaconess Hospital and Beth Israel Deaconess Medical Center 2000-2002 Elected Member, Faculty Council Harvard Medical School 2005-2012 Member, Subcommittee on admission of students in the Faculty of Medicine, M.D.-Ph.D. Program Harvard Medical School 2006 Chair, Search Committee for Assistant Professor of Pathology Harvard Medical School 2006 Member, Pathology Faculty Search Committee for Assistant Professor at the Department of Pathology Beth Israel Deaconess Medical School 2007 Chair, Promotion Committee to Professor of Surgery Harvard Medical School 2008-2010 Member, Benjamin Castleman Award Committee United States and Canadian Academy of Pathology, Inc., (USCAP), Augusta, GA 2009 Co-Leader, Task Force on Personalized Medicine Dana-Farber/Brigham & Women’s Hospital, Boston, MA 2009 Member, External Review, Department of Pathology, Brigham & Women’s Hospital Brigham & Women’s Hospital, Boston, MA 2010 Member, Search Committee for Women’s and Pre-natal Division Investigator, Assistant Professor of Pathology Harvard Medical School 2010 Chair, Ad Hoc Committee of evaluators for appointment of Professor of Medicine (Area of Excellence: Clinical Expertise with significant activity in Investigation) Harvard Medical School and Massachusetts General Hospital 2010-2012 Member, Standing Committee on Promotions, Reappointments, and Appointments Harvard Medical School 2010-present Member, Radiology Research Working Group Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) 2012-present Member, Dana-Farber Committee for Faculty Promotions and Appointments (DFCPA) Dana-Farber Cancer Center 2009 Member, Tissue-based Biomarker Assays Subcommittee Biomarkers Task Force, Investigational Drug Steering Committee (CTEP), National Cancer Institute 2010-present Co-Chair, The Cancer Genome Atlas (TCGA) Prostate Disease Working Group 4 National Cancer Institute, National Institutes of Health, Bethesda, MD Committee Service Local 1993-1996 Loda - CV 2016 Co-Chair, 2016 Annual Meeting Program Committee American Association of Cancer Research (AACR), Philadelphia, PA Thesis Advisory Committee Dissertation Defense of National and International graduate students 11/15/2011 12/5/2011 3/1/2015 Stacey Lynn Eggert Ph.D. Candidate in Biological and Biomedical Sciences - Harvard University Dissertation Defense of Alexis Ramos Ph.D. Candidate in Biological and Biomedical Sciences - Harvard University “Identification and Characterization of Genetic Variants Conveying Risk to Uterine Leiomyomata” “Cancer Genome Characterization using DNA Sequencing and SNP Array Analysis” Dissertation Defense of Margrethe Storm: “Molecular mechanisms of androgen effects on prostate cancer cells”Department of Biosciences, Faculty of Methematics and Natural Sciences, University of Oslo, Norway Professional Societies 1989The US and Canadian Academy of Pathology, Member 1992The American Association of Cancer Research, Member 1992The New England Society of Pathologists, Member 1993The Endocrine Pathology Society, Member 2003American Society of Investigative Pathology, Member 2015 Member, Association of American Physicians Grant Review Activities 1994 1996 1996 19992000-2002 2003 2004-2007 2005 2005-2008 2005-present 2007 2008 2009-2013 2013 VA Granting Office, Reviewer Chemoprevention Branch, National Cancer Institute, Ad-Hoc Reviewer Medical Research Council of Canada, Reviewer National Cancer Institute, Ad Hoc Reviewer Department of Defense, Prostate Cancer Research Program, Member, Study Section, Pathobiology Associazione Italiana Ricerca sul Cancro (AIRC), Reviewer Cancer Research UK, Reviewer Department of Defense, Prostate Cancer Research Program, Member, Study Section, Pathobiology NCI, Molecular Oncogenesis (MONC), Ad Hoc Member, Study Section United States and Canadian Academy of Pathology (USCAP) 2005-2011, Abstract Review Board 2007-2011, Abstract Reviewer, Pathobiology section, USCAP Prevention, Control and Population Sciences, NCI, Ad Hoc member, Special Emphasis Panel Samuel Waxman Cancer Research Foundation, Reviewer Department of Defense, Congressionally Directed Medical Research Program, Member, Prostate Cancer Research Program, Integration Panel Member Quinquennial Review for Cancer Research UK, Prof. Caldas’ group. Cambridge, England Member of international review panel. 5 Loda - CV Editorial Activities Serve on Editorial Board for the following journals: 2006-2012 1994-present 2005-present 2009-present 2010-2012 2012-2013 American Journal of Clinical Pathology Diagnostic Molecular Pathology Cell Division Laboratory Investigation Associate Editor, American Journal of Pathology American Journal of Pathology, Editorial Boad member Consulting Editor, BJU International Journal 2012-present Editorial Board, American Journal of Pathology Ad-Hoc Reviewer for the following Journals: Nature Science New England Journal of Medicine Cell Metabolism Journal of Clinical Oncology Nature Medicine Cancer Cell Oncogene Journal of Clinical Investigation Modern Pathology Cancer British Journal of Cancer Blood Journal of the National Cancer Institute Human Pathology Cancer Research The Prostate Breast Cancer Research Molecular Carcinogenesis British Journal of Urology Other and Former Editorial Roles 1998-2000 Former Member, Editorial Board 2001-2002 Former Member, Editorial Board 2002-2007 Former Member, Editorial Board 2007 Former Member, Editorial Board 2007-2010 Former Senior Editor 2008-2011 Former Member, Editorial Board The Prostate Journal Journal of Clinical Pathology The American Journal of Oncology Review Clinical and Translational Science (CTS) Clinical Cancer Research American Journal of Translational Research Honors and Prizes 1980 1995 MD, Summa cum laude CaP CURE Award University of Milan Association for the Cure of 6 Academic Achievement Research Loda - CV 1997 Stowell-Orbison Award 1997 CaP CURE Award 1998 1998 The Claudia Adams Barr Investigator in Cancer Research Award The Daland Award 2001 CaP CURE Award 2003 CaP CURE Award 2003 Donald S. Coffey-CaP CURE PhysicianScientist Award 2005 Cancer of the Prostate, Santa Monica, CA US and Canadian Academy of Pathology Association for the Cure of Cancer of the Prostate Dana-Farber Cancer Institute Clinical/Research Research Research and Clinical Innovation The New England Cancer Society Worcester, MA Association for the Cure of Cancer of the Prostate Association for the Cure of Cancer of the Prostate Association for the Cure of Cancer of the Prostate Research Prostate Cancer Foundation Research Award Prostate Cancer Foundation Research 2012 Challenge Award Prostate Cancer Foundation Research 2015 Nominated Officer (Knighthood) President of the Republic of Italy Research of the Order of the Star of Italy (Ufficiale dell'Ordine della Stella d'Italia) 2015 Elected Member Association of America Physicians Clinical/Research 2015 Nominated Member Tumor Cell Biology Study Section Reserach NCI (4 year term) 2015 Research Research Clinical/Research Report of Funded and Unfunded Projects Funding Information Past Grants: 1984-1985 NIH Endocrine factors in recovery from surgical trauma, Co-investigator 1984-1985 University Hospital, Boston, MA, Principal Investigator Role of Interleukin 1 and hormones in the hepatic acute phase response. 1985-1988 Armed Forces Radiobiology Research Institute, Bethesda MD and Naval Blood Research Laboratories, Boston, MA, Co-investigator Combined radiation and burn injury, the role of primary excision and wound closure. 1991-1992 Ministero della Pubblica Istruzione, Rome, Italy, Consultant Medulloblastoma cell lines in vitro and in vivo. 1991-1992 Ministero della Sanità, Rome, Italy, Co-investigator HIV damage in the central nervous system. 7 Loda - CV 1992-1993 Associazione Italiana Ricerca sul Cancro (AIRC), Milan, Italy, Co-investigator Point mutations in Gs proteins in thyroid neoplasms. 1992-1993 Associazione Italiana Ricerca sul Cancro, Co-investigator Study of homeobox sequence-harboring genes in growth and differentiation of primitive CNS neoplasms. 1993-1994 Serono, Geneva, Switzerland, Co-investigator Hormonal regulation of prostate cancer. 1994 CaP CURE award, Prostate Cancer Foundation, Principal Investigator Role of MKP-1 in prostate cancer. 1994-1999 NIH - PO1, Principal Investigator, Pathology Core The pathobiology of colorectal cancer. 1995 Oncor, Inc., Principal Investigator Evaluation of the Oncor HER-2/neu (ERBB2) gene amplification detection kit for the interphase detection of HER-2/neu (ERBB2) genomic sequences in human breast tissue for node-negative, primary breast cancer. Multistudy for FDA approval of the HER-2/neu (ERBB2) gene amplification detection kit. (Kit FDA approved Jan 1998). 1995-1996 Mitotix, Inc. Principal Investigator CDC 25 expression in human tumors. 1996 CaP CURE Foundation, Prostate Cancer Foundation, Principal Investigator Role of p27 in prostate cancer. 1996-1997 Beth Israel Deaconess Medical Center, West Campus, Principal Investigator In house grant for exploratory projects. Role of ubiquitin-proteasome pathway in prostate cancer. 1998-2000 Barr Investigator, Dana Farber Cancer Institute, Principal Investigator Role of MKP-1 in prostate cancer. 1998-2001 DOD-ARMY, Principal Investigator Androgen regulation of p27 in the normal and neoplastic prostate. 1998-2002 NIH/NCI RO1, Principal Investigator Isopeptidases, ubiquitin-degradation and prostate cancer. 1998-2003 NIH/NCI RO1 (UCLA - Harvard), Principal Investigator, subcontract Stem cell genes in human prostate growth and differentiation. 1999-2000 Massachusetts Department of Public Health, Principal Investigator Functional identification of prostate cancer genes directing carcinogenesis and tumor progression. 1999-2005 NIH UO1, Co-Investigator Gene expression analysis of cancers of the prostate and lung. Director’s challenge RFA. 2000-2004 DFCI/Novartis Drug Discovery program grant, Principal Investigator Role of p63 in prostate development: an animal model. 2000-2005 NIH PO1, Principal Investigator The role of PTEN and the PI3K pathway in prostate cancer. 2000-2005 DF/HCC grant application, Principal Investigator Molecular in situ hybridization core. 8 Loda - CV 2000-2005 DF/HCC grant application, Principal Investigator Human Pathology Core for Prostate Cancer. 2001 Tisch Family Fund Award, Principal Investigator Therapeutic Potential of Cdk Inhibitors in Barrett’s Associated Adenocarcinoma. 2001-2006 NIH P01, Co-Investigator of Project #2 Prospective study of Diet and Colorectal Neoplasia. 2002 CaPCure Award, Principal Investigator The Isopeptidase USP2 as a Prostate Oncogene. 2002-2007 NIH/NCI CA90381 (Kantoff, DFCI), Principal Investigator of Pathology Core SPORE in Prostate Cancer. 2004-2005 Howard Hughes Medical Institute/SPORE, Principal Investigator Biomedical Research Support Program / Pilot Project Research Award. Validation of expression profiling at the cellular level. 2003-2004 DF/HCC grant for Core Technology Developments, Principal Investigator Biological Imaging Spectroscopy. 2004 RFA on Cancer Detection, Dana Farber Cancer Institute, Principal Investigator Fatty Acid Profiles as Potential Biomarkers in Prostate Cancers. 2004 DFCI/Novartis Drug Discovery Program, Principal Investigator USP2a and Fatty Acid Synthase (FAS) as molecular targets in prostate cancer. 2004 Friends of Dana Farber Cancer Institute, Principal Investigator High Throughput Quantitation of Gene Expression in Tissue Microarray. 2004-2006 P01 Diet, Hormones, and Risk of Colorectal Cancer. Co-Investigator of Project #2 Dietary and Hormonal Determinants of Cancer in Women. 2004-2007 SPORE Pilot project, Principal Investigator USP2a as a molecular target in prostate cancer. 2005 Prostate Cancer Foundation , Principal Investigator Fatty acid synthase as a metabolic oncogene in prostate cancer. 2005 Nuclea, Inc. , Principal Investigator Biomarkers in Cancer. 2005-2006 Novartis/DFCI Drug Development Program, Principal Investigator USP2a and Fatty Acid Synthase (FAS) as Molecular Targets in Prostate Cancer. 2005-2008 DOD – Idea Development Award, Principal Investigator Mouse orthotopic xenographs of human prostate primary tumors. 2007-2008 Novartis -DFCI Drug Development Program, Principal Investigator Evaluation of drug target and pathway expression patterns in human tumors using quantitative in situ expression analysis tumors using quantitative in situ expression analysis. 2005-2009 NIH R01CA101034 (Halperin, HMS), Co-Investigator Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids. 2005-2010 NIH/NHLBI T32 HL007627 (Gimbrone, BWH), Faculty 9 Loda - CV Vascular, Pulmonary and Renal Injury 2006-2010 NIH/NCI P01 CA87969 (Hankinson, BWH), Co-Investigator Dietary and Hormonal Determinants of Cancer in Women: Project 2. 2006-2007 Merck & Co, Inc., Principal Investigator Joint development of fluorescence in situ hybridization (FISH) protocol to detect amplification status of MET gene in human tumors. 2006-2008 Samuel Waxman Foundation (Sawyers/MSKCC), Co-Investigator Elucidating Signatures of Pathway Activation and the Effects of Molecularly Targeted Therapy in Prostate Cancer Mouse Models and Patients. 2008-2009 Novartis-DFCI Drug Development Program, Co-Investigator (Loda lab, CMOP) AMPK, the Metabolic Syndrome and Prostate Cancer . 2008-2009 Friends of Dana-Farber, Co-Investigator (Loda lab) Qiagen BioRobot Universal System for Cancer Genomic Laboratories 2008-2009 Prostate Cancer Foundation (Kantoff), Co-Invesgtigator CaP Cure Therapy Consortium Emphasis is to support the correlative and translational science that surrounds clinical trials and clinical investigation on prostate cancer. 2007-2012 mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance NIH/NCI R01CA123175 (Febbo, Duke University), Co-Investigator Overall goal of the work proposed is to improve the care of men with prostate cancer by providing predictive markers and identify potentially synergistic combination therapy. 2008-2013 Research Fellowship in the Center for Molecular Oncologic Pathology (CMOP) Nuclea Biotechnology Projects involve novel applications of molecular cytogenetic technologies specific to prostate cancer. 2008-2013 DF/HCC Lung Cancer SPORE: Core A – Tissue and Pathology Core NIH/NCI P50 CA90578 (Johnson, B/DFCI) Director, Pathology Core ($55,079, DFCI Only) 2007-2013 The role of PTEN and P13K pathway in prostate cancer – Pathology Core NIH/NCI P01 CA89021 (Cantley, L/BIDMC) Core Director $137,551 (Pathology Core) The aim of the project was to assess the role of P13K pathway in prostate cancer development utilizing animal models in human tumors. Past and Present Mentored Grants 2006-2008 American-Italian Cancer Foundation Fellowship (D. DiVizio, Children’s Hospital) Fatty acid synthase and caveolin-1 in prostate cancer. 2007 Fulbright Scholarship (E. O’Regan, BWH) Focusing on the cause of head and neck cancer in people younger than 40 2007-2009 Harvard SPORE in Breast Cancer Fellowship 10 Loda - CV (E. Snyder, DFCI) Identification and characterization of putative breast cancer stem cell in situ using quantum dot-conjugated antibodies. 2007-2008 American-Italian Cancer Foundation Fellowship (Palescandolo, DFCI) Palmitoylation signature in prostate cancer cell lines. 2007-2008 University of Milan Fellowship (Benedettini, DFCI) The role of MET in metastasis: analysis of MET status and activation in metastatic gastric cancer or non small cell lung cancer (NSCLC). 2007-2008 American-Italian Cancer Foundation Fellowship (Zadra, DFCI) AMPK: a potential target in prostate cancer. 2008 TRP-22 project #122 RTOG Clinical Trials (Nguyen, BWH) The Impact of p27 Expression on Outcome of RTOG 86-10. 2008-2009 P.A.R.T. Investigatorship in Prostate Cancer Award (Priolo, DFCI) Integrative models to define metabolic signatures in human prostate tumors: toward new anti-metabolic approaches in cancer therapeutics. 2009 Brigham & Women’s Hospital Department of Pathology (A. Ligon, BWH) Eleanor and Miles Shore 50th Anniversary Fellowship for Scholars in Medicine 2011 Joe Pashcow- PCF Young Investigator Award (K. Penney, HMS) Advance molecular Gleason signature into clinical validation and investigate the biological pathways that underlie tumor aggressiveness. If validated in biopsy tissue, 157-gene signature will improve outcome prediction and clinical decision making for PCa patients at the time of diagnosis. 2011-2013 The A. David Mazzone Career Development Award, DF/HCC (K. Penney, HSPH) The association of known prostate cancer geneticrisk variants with gene expression in normal prostate and tumor tissue as well as molecular subtypes of prostate cancer, defined by PTEN, MYC,and TMPRSS2:ERG. Will ascertain biological pathways that explain the link between genetic riskvariants and PCa. 2011–2014 Gleason-based mRNA and metabolomic profiling to predict prostate cancer outcomes Prostate Cancer Foundation (K. Penney, HSPH) $75,000 To determine if the previously identified signature for lethal disease can be applied in the clinic, we will further validate and test its predictive ability in tissue at the time of diagnosis. 2011–2014 Characterizing the activation of PI3Kinase in prostate cancer Prostate Cancer Foundation (N. Martin, BWH) $75,000 To determine if the previously identified signature for lethal disease can be applied in the clinic, we will further validate and test its predictive ability in tissue at the time of diagnosis. Current Grant Funding: 09/26/08- Metabolic Syndrome, Fatty Acid Synthase and Prostate Cancer 11 Loda - CV 07/31/13 NIH/NCI R01 CA131945 – renewal pending PI ($145,250, DFCI only) Administrative supplement award, 2009 The overarching hypothesis of this proposal is that high levels of FAS result from sustained AMPK inhibition, as occurs in the metabolic syndrome. To validate this hypothesis, we propose to utilize a multidisciplinary approach that combines cell biology, animal model studies, human prostate cancer samples and inherited genetic changes (utilizing large patient populations) that confer susceptibility to prostate cancer. 12/14/1112/13/14 Shedding light on stromal – epithelial interactions in prostate cancer carcinogenesis and mortality Prostate Cancer Foundation Challenge award PI ($1,000,000) The proposed study will test and validate critical pathways in the stromal-epithelial environment associated with prostate carcinogenesis, illuminate alterations in pathways in the microenvironment that drive lethal disease, and develop novel bioinformatic tools to characterize stromal-epithelial cross-talk. We propose to integrate genome wide mRNA and miRNA expression data in cohorts from the US, Sweden and Ireland, and to translate results to detect novel chemopreventive and therapeutic strategies. 12/01/05– 11/30/12 Dana-Farber/Harvard Comprehensive Cancer Center: Pathology Core NIH/NCI P30 CA06516 (Benz, E/DFCI) The goals of this grant are to develop and maintain clinical/laboratory research programs of high quality related to the biology, cause and prevention, diagnosis and treatment of cancer; to serve as the major cancer center in the Harvard-Longwood Medical Area; to play a leadership role for cancer research and patient care in New England; and teaching/training of students, interns, residents, fellows/post-docs and graduate students. 04/15/0606/30/15 Genetics and Biology of Pancreatic Ductal Adenocarcinoma – Experimental Pathology Core B NIH/NCI P01 CA117969 (DePinho, R/DFCI) Director, Pathology Core (NCE) The goal of this P01 is to further elucidate the genetics and biology of the disease to a level that will guide the rational development of effective targeted agents, alone and in combination. 08/31/07– 06/30/12 DF/HCC SPORE in Gastrointestinal Cancer: Core 2 – Tissue and Pathology Core (NCE) NIH/NCI P50 CA127003 (Fuchs, C/DFCI) The main goal of the Specialized Program of ResearchExcellence (SPORE) of Gastrointestinal Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and avances in the treatment of gastrointestinal malignancies. 09/01/0706/30/13 DF/HCC SPORE in Prostate Cancer: Pathology Core (NCE) NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Director, Pathology Core The major aims of this coare are to 1) provide a tissue and blood repository for use by SPORE investigators, 2) to provide research pathology services to SPORE investigators, including histology, immunochemistry, in situ hybridization, computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays. 09/01/0706/30/13 DF/HCC SPORE in Prostate Cancer: Pathology Core (NCE) NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Co-Director, Project 3 TMPRSS2:ERG and SPINK1 in Lethal Prostate Cancer The overall hypothesis is that there are three mutually exclusive PCa subtypes: TMPRSS2: ERG positive, SPINK1 positive and Fusion/SPINK1 negative. An understanding of lethal PCa in the context of TMPRSS2: ERG and SPINK1 molecular alterations is currently lacking. The project proposes a comprehensive study 12 Loda - CV utilizing the Physicians’ Health Study and Health Professionals Follow-up Study among 1,500 men with PCa, of whom 175 developed lethal disease. 09/30/0908/31/14 Targeting Tumor Suppressor Phosphatases for Cancer Therapy NIH/NCI U01 CA141496 (PI: Pandolfi) This application aims to characterize the role of critical tumor suppressor phosphatases in human cancer and exploit the therapeutic potential of a novel type of senescence mechanism that we have discovered to arise in response to their acute inactivation. The project focuses on the potential for the development of novel therapies for the treatment of cancer through the targeting of the cancer stem cell. 03/03/091/31/14 Sex Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer progression NIH/NCI R01 CA136578 (Mucci, BWH) Site PI The overall aim is to determine how SPINK1 and TMPRSS2: ERG fusion define the lethal phenotype of PCa and will estimate the utility of these molecular subtypes on risk stratification. 05/01/1004/30/15 Prognostic and Predictive Biomarkers Research Nuclea Biotechnology PI ($474,090) Overall goal is to develop a biomedical database of prognostic/predictive biomarkers derived from IHC survey of tumor microarrays, for use in diagnostics. 05/01/1002/28/14 Growth Factors and Lethal Prostate Cancer Signature R01CA141298 (Stampfer, M/BWH) PI of subcontract The proposal is to apply a novel but proven high-throughput profiling technology to assess RNA expression in archival tumor tissue using a 24,000 gene platform. The overall goal is to distinguish prostate cancers that are incolent, and can safely be left untreated, from those that are potentially lethal and require aggressive therapy. 02/01/10 – 1/31/13 The Cause and Consequence of Centrosome and Ploidy Abnormalities in Human Cancer using Barrett’s Esophagus as a Model HMS Portugal Program (Golan/HMS) The overall goal is to define the relationship between centrosome abnormalities, known defects in genes and global changes in chromosome content. 09/12/11 – 7/31/16 Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies NIH/NCI R01 CA155301 (Gann, P/U-ILL) $15,746 Aims: 1) To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue; 2) To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not; and 3) To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. 07/01/12 – 6/30/14 Developing a Blood-based Metabolomic Signature of Gleason Score A David Mazzone Awards Program .60 Calendar Months Principal Investigator ($50,000) We propose to perform metabolic profiling on blood collected before and after RP; comparisons between these samples can help confirm that significant metabolites are truly influenced by the 13 specific Loda - CV tumor (or the prostate) and not other characteristics. 09/30/13 – 09/29/16 Toward the Practice of Precision Medicine: A Biomarker Validation Coordinating Center DOD W81XWH13-2-0070 Principal Investogator To revolutionize the clinical management of prostate cancer— to enable the practice of precision medicine in the near term—by developing analytically validated assays for predictive biomarkers of sensitivity to AR and PI3K inhibitors for use in prospective clinical trials at all points in the disease 07/01/14 – 6/30/19 DF/HCC SPORE in Prostate Cancer: Pathology Core NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Director, Pathology Core The major aims of this coare are to 1) provide a tissue and blood repository for use by SPORE investigators, 2) to provide research pathology services to SPORE investigators, including histology, immunochemistry, in situ hybridization, computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays. 07/01/14 – 6/30/19 DF/HCC SPORE in Prostate Cancer NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Principal Investigator, Project 2 We propose to build upon our promising expression profiling findings with the following aims: 1) Preparation and testing of Gleason signature of lethal disease for clinical use, 2) Metabolomics of Gleason grade in tumor as predictor of lethal disease, and 3) Metabolomics of Gleason grade in serum as biomarker for upgrading. 07/01/14 – 6/30/19 DF/HCC SPORE in Gastrointestinal Cancer: Core 2 – Tissue and Pathology Core NIH/NCI P50 CA127003 (Fuchs, C/DFCI Core Director ($147,790) The main goal of the Specialized Program of ResearchExcellence (SPORE) of Gastrointestinal Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and avances in the treatment of gastrointestinal malignancies. 7/01/14 – 06/30/17 DoD Synergy Award– PC130716 (Loda) PI DFCI, U. Mahmood (PI, MGH) $700,000 In vivo Targeting and Imaging of the lipogenic Phenotype of Prostate Cancer Principal Investigator The goals of this project are to assess whether AMPK activation inhibits castration-resistant prostate cancer (CRPC) growth in vivo. To investigate the biographic relevance of combining AMPK activators or FASN inhibitors with AR signaling inhibitors as a synergic therapeutic strategy for CRPC. Report of Local Teaching and Training Teaching of Students in Courses 1988-1989 Pathology Laboratory tutor Medical students Tufts University School of Medicine, Boston, MA 1-5 hours daily for the duration of the course 14 Loda - CV 1989-1994 Faculty member 4th, 5th, 7th, 9th Molecular Pathology workshops Tufts University School of Medicine 4 day course 1994-1999 Laboratory Leader: Identity Microbes and Defense 50 Medical Students Harvard Medical School 4-6 hours before each session to present ½ hour lecture and go over slides with Medical Students 1995 Soma Weiss student research assembly – supervised project for medical students entitled “Expression of somatostatin receptors 1-4 in colorectal neoplasms” Poster Presentation Harvard Medical School 1997 Tutor, HMS Pathology course, Peabody Society 8-10 Medical Students Harvard Medical School 4-6 hours before each tutorial session 2000-2007 Yearly lecture to the Division of Health Science and Technology HST: “Frontiers: novel probes of cell function” (Combined Harvard/MIT human Pathology Course) Harvard Medical School Director of yearly Boot-Camp Course: “Molecular Pathology of Cancer”: Lecturer and lead faculty for 2-week lecture series Harvard Graduate Ph.D. Students Harvard Medical School 2010- present 2009-present Supervised project for medical students 1 hour per lecture 30 hours AACR - Translational Cancer Research for Basic Scientists Workshop. “Diagnostic Molecular Pathology” 1 day/year Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs) 1990-1992 Resident Training Deaconess Hospital 18 residents ~10 hours daily every week 1990-1992 Lecturer in Pathology, Residency training program in Anatomic Pathology and Medical Oncology 50-100 Medical Students and residents University of Bologna School of Medicine, Bologna, Italy 15-20 hours to prepare 4-5 lectures 1992-1998 Resident Training 38 residents Beth Israel Deaconess Medical Center ~10 hours daily every week 1996-1998 Director, Diagnostic Molecular Pathology Laboratory Formal resident rotations within the lab; Taught a series of 8 lectures per year on Molecular Pathology Beth Israel Deaconess Medical Center 1997-1998 Resident Training 12 residents University of Bologna, Bologna, Italy ~5 hours daily every week 1998-present Resident Training 41 residents Brigham & Women’s Hospital 1-5 hours daily every week on service plus 3 teaching lectures per year on genito-urinary pathology 1998-present Director, Center for Molecular Oncologic Pathology Dana-Farber Cancer Institute and Brigham & Women’s Hospital 15 Formal rotations were in one-month durations, also lectured on a weekly basis as part of the Clinical Pathology lecture series Loda - CV 1998-present As a BWH Faculty member, I am responsible for the interviewing and recruitment of pathology residents Genitourinary Pathology Fellows Dana-Farber Cancer Institute and Brigham & Women’s Hospital 1-2 hours weekly Clinical Supervisory and Training Responsibilities 1992-1996 Director, Diagnostic Immunohistochemistry Laboratory; Director, Diagnostic Molecular Pathology Laboratory / Deaconess Hospital 15 hours per week 1996-1998 Director, Diagnostic Molecular Pathology Laboratory / Beth Israel Deaconess Medical Center 20 hours per week 1998-2005 Director of In Situ Hybridization and Prostate Pathology Core facilities / Dana-Farber/Harvard Cancer Center 20 hours per week 2007-2010 Director, Genito-Urinary Pathology service, Department of Pathology, Brigham & Women’s Hospital 5 hours per week Laboratory and Other Research Supervisory and Training Responsibilities 1992-1996 Director, Diagnostic Immunohistochemistry Laboratory; 15 hours per week Director, Diagnostic Molecular Pathology Laboratory / Deaconess Hospital 1996-1998 Director, Diagnostic Molecular Pathology Laboratory / Beth Israel Deaconess Medical Center 20 hours per week 1998-2005 Director of In Situ Hybridization and Prostate Pathology Core facilities / Dana-Farber/Harvard Cancer Center 20 hours per week 2006-present Director, Center for Molecular Oncologic Pathology (CMOP), Dana-Farber Cancer Institute/Brigham and Women’s Hospital 15 hours per week 2007-2010 Director, Genito-Urinary Pathology service, Department of Pathology, Brigham & Women’s Hospital 5 hours per week 1992-present Supervision of post-docs and graduate students in the lab, Dana-Farber Cancer Institute Daily Mentorship Formally Supervised Trainees 1994-1996 Paola Capodieci, Ph.D. / Investigator III, Novartis, Cambridge, MA. Project title: MKP1 in different Cancer Types / Source of funding: NIH grant 1995-1998 Cristina Magi-Galluzzi, M.D. / Professor of Pathology, Case Western Reserve University, Director of genito-urinary pathology service, Cleveland Clinic, Cleveland, OH Project Title: Role of Mitogen activated protein kinase phosphatase 1 (MKP-1) in prostate cancer / Source of funding: Industry sponsored research (PI: M.L.) 1996-1997 Mira Mandoki, Ph.D. / Assistant professor, Department of Pathology and Forensic Veterinary Medicine, Faculty of Veterinary Science, Szent Istvan University, Hungary Project Title: Molecular diagnostic work: - detection of Factor V. Leiden mutation by PCR and RFLP, detection of hepatitis C with Amplicor HCV Monitor (Roche) test, - in situ hybridization: HPV. Research projects: - C\EBP alpha, - prolactin receptor in human prostate cancer / Source of Funding: Molecular 16 Loda - CV diagnostic laboratory (Dr. Loda) 1998-2003 Sabina Signoretti, M.D. / Independent Investigator and Associate Professor of Pathology, Brigham & Women’s Hospital Project Title: p63 and prostate stem cells: an animal model / Source of funding: PO1 (PI: Cantley, BIDMC), SPORE (PI: Kantoff, DFCI), Novartis Investigator grant (PI: M.L.), DOD (New Investigator award with Dr. Signoretti as PI while in my lab) 1999-2001 Douglas Lin, M.D., Ph.D. / Attending Pathology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Project Titile: SKP2 and its role in Prostate Cancer. Currently Resident in Pathology, Brigham and Women’s Hospital 1999-2002 Edgard Graner, D.D.S., Ph.D. / Associate Professor, Department of Oral Diagnosis, School of Dentistry of Piracicaba, University of Campinas (UNICAMP), State of Sao Paulo, Brazil, Av. Limeira 901, CP 52, Areao, Piracicaba, SP, Brazil CEP 13414-018" Project Title: Discovery of novel de-ubiquitinating enzymes in prostate cancer / Source of funding: RO1 (PI: M.L.) 1999-2002 Giulia Cangi, Ph.D. / Staff Scientist and Investigator, Department of Pathology, University Vita e Salute, S. Raffaele Hospital, Milan, Italy Project Title: Role of the dual-specificity phosphatase cdc25A in breast cancer / Source of funding: RO1 (PI: M.L.) 1999-2002 Sabrina Rossi, M.D. / Staff Pathologist, Ospedale Ca’ Foncello, Treviso, Italy Project Title: Expression profiling of Fatty Acid Synthase expressing prostate carcinomas / Source of funding: PO1 (PI: Cantley, BIDMC) 2000-2002 David Waltregny, M.D., Ph.D. / Academic Urologist, Professor of Pathology, University Hospital of Liege, Belgium Project Title: p27 regulation in a rat model of castration and testosterone-induced prostate regeneration / Source of funding: DOD (PI: M.L.) 2000-2002 George Thomas, M.D. / Former position: Assistant Professor of Pathology, UCLA School of Medicine; Reader in Molecular Pathology, Chester Beatty Laboratories and The Royal Marsden Hospital, London and Sutton – Currently: Surgical Pathologist: Oregon Health & Science University (OHSU), Portland, OR Project title: Role of p27 in the development of colon metastases in human tumors / Source of funding: RO1 (Massimo Loda, PI) 2001 Alessia Baccarini, Ph.D. / Instructor, Genetics and Genomic Sciences, Mt. Sinai School of Medicine, New York, NY Project Title: Analysis of CKS1 gene in prostate tissue 2001-2004 Shuji Ogino, M.D., Ph.D. / Associate Professor of Pathology (BWH and Dana Farber Cancer Institute) Project Title: Molecular Pathology and Epidemiology of Colorectal Neoplasias / Source of Funding: PPGs (PIs, Willett, Colditz), R01 (PI, Fuchs) 2001-2004 Mirna Lechpammer, M.D., Ph.D. / Fellow in Neuropathology, BWH Project Title: Chemoprevention of Barrett’s Associated Adenocarcinoma by cdk inhibitors in a mouse model / Source of funding: Tisch grant 2002-2004 Antonella Baron, Ph.D. / Postdoctoral Fellow- Laboratory of Urological Malignancies at Venetian Institute of Molecular Medicine (VIMM), Padua, Italy Project Title: Analysis of CKS1 gene in prostate tissue. / Source of Funding: NIH Grant 2002-2005 Dan Tang, M.D., Ph.D. / Internal Medicine Physician, Mount Auburn Hospital, Cambridge, MA Project Title: The USP2a isopeptidase in prostate cancer 17 Loda - CV 2002-2007 Toshiro Migita, M.D., Ph.D. / Research associate, Japanese Foundation for Cancer Research, The Cancer Institute of JFCR, Department of Pathology, Japan Project Title: Fatty acid synthase as an oncogene in prostate cancer. / Source of Funding: Prostate Cancer Foundation 2004-2005 Wei Huang, M.D. /Assistant Professor, Dept. of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2004-2006 Dolores Divizio, M.D., Ph.D. /Staff Scientist, Children’s Hospital, Boston, MA Project Title: Fatty acid synthase and caveolin-1 in prostate cancer 2004-2011 Carmen Priolo, M.D., Ph.D. / Instructor in Medicine, Harvard Medical School and Faculty member, Pulmonary and Critical Care Medicine (PCCM) Division at Brigham and Women’s Hospital Project Title: Integrative models to define metabolic signatures in human prostate tumors: toward new antimetabolic approaches in cancer therapeutics. / Source of Funding: P.A.R.T Investigatorship in Prostate Cancer Award 2006-2007 Tarek Bismar, M.D., Ph.D. / Associate Professor, University of Calgary, Faculty of Medicine, Calgary, AB Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2006-2007 Stephen Finn, M.D., Ph.D. / Associate Professor, University of Dublin Trinity College and St. James’s Hospital. Project title: Quantum dot applications in pathology. / Source of Funding: Center for Molecular Oncology Pathology (CMOP) 2006-2007 Stacy Ruiz, Ph.D. / Associate Director, Product Development, Reata Pharmaceuticals, Dallas, TX Project title: The role of AMPK as a therapeutic target for treating prostate cancer. 2006-2009 Zhiqian Liu, Ph.D. / Scientist, Biogen Idec, Boston, MA Project Title: The role of USP2a in EGFR endocytosis / Source of Funding: DOD Grant (Loda) 2006 Richard Mollow / Dr. Loda served as Mr. Mollow’s thesis advisor at Harvard Extension School Thesis title: “Use of Second Generation Monoclonal Immunoassay to Improve Sensitivity and Specificity in Prostate Cancer Screening for American Males” 2006-2010 Rosina Lis, M.D., Ph.D. / Research Scientist/ DF/BWH Center for Molecular Oncologic Pathology Project Titles: 1) DF/HCC SPORE in Gastrointestinal Cancer: Core 2 – Tissue and Pathology Core, 2) Multi-Spectral Imaging Research Fellowship. / Source of Funding: 1) NIH/NCI: DF/HCC SPORE in Gastrointestinal - Core 2, 2) Industry: Nuclea Biomarkers, LLC 2007-2012 Giuseppe Fedele, M.D. / Senior resident in Psychiatry, Mount Sinai School of Medicine, NY Project Title: Use of genetically engineered mouse models to determine the role and interactions of Fatty Acid Synthase and the master energy regulator AMPK in prostate cancer pathogenesis. / Source of Funding: GELB Center for Genitourinary Oncology, Dana-Farber Cancer 2006-2009 Elisa Benedettini, Ph.D. / Research Fellow, Bufalini Hospital, Cesana, Italy Project Title: The role of MET in metastasis: analysis of MET status and activation in metastatic gastric cancer or non small cell lung cancer (NSCLC) patients. / Source of Funding: Fellowship from University of Milan 2006-present Ewa Sicinska, M.D. / Senior Research Scientist, CMOP Project: Mouse xenograft model of human sarcoma, DF/BWH CMOP / Source of Funding: Center for Molecular Oncology Pathology (CMOP) 2006 Emanuele Palescandolo, Ph.D. / Research Scientist and Group Leader, Center for Cancer Genome Discovery, CCGD, Currently, group leader, Leuven University, Belgium Project Title: Palmitoylation signature in prostate cancer cell lines. / Source of Funding: AICF Fellowship 18 Loda - CV Summer, 2007 Esther O’Regan, Ph.D. / Assistant Professor of Pathology, Trinity College, Dublin, Ireland. Awarded Fulbright scholar status to continue her work on head and neck carcinoma with Dr. Massimo Loda at DFCI. / Source of Funding: Center for Molecular Oncology Pathology (CMOP) 2007-present Giorgia Zadra, Ph.D. / Postdoctoral Fellow, Loda lab. Currently Instructor in Pathology, Department of Pathology, Brigham & Women’s Hospital, Boston, MA Project Title: AMPK: a potential target in prostate cancer / Source of Funding: AICF Fellowship 2007-2008 Eric Snyder, M.D., Ph.D. / Postdoctoral Fellow, Tyler Jacks lab, MIT. Currently Assistant Professor of Pathology, UCSF, San Francisco, CA Project: DF/HCC SPORE in Breast Cancer. / Source of Funding: funding via BWH 2008 Alessandro Fornari, M.D. / Staff Pathologist, University of Turin, Italy Project: Responsible for a project aimed at the translation of gene expression profile signatures in paraffin embedded tissue. / Source of Funding: University of Turin, Italy 2008 Paul Nguyen, M.D. / Instructor in Radiation Oncology, Harvard Medical School and Attending Physician in Radiation Oncology BWH/DFCI Project Title: The Impact of p27 Expression on Outcome in RTOG 86-10. / Source of Funding: RTOG 2008-2010 Neil Martin, M.D. / Assistant Professor of Radiation Oncology/Harvard Medical School; and Attending at BWH, DFCI, CHB, Boston, MA Project Title: Investigation of PI3K activation in prostate cancer. 2008-2010 Bernadette Wildemore, M.D. / Physician in Anatomic & Clinical Pathology in Philadelphia, PA Project Title: Research Fellowship in the DF/BWH Center for Molecular Oncologic Pathology (CMOP) 2008-2011 Shamini Selvarajah, Ph.D. / Clinical Cytogenetics Fellow, Harvard Medical School Genetics Training Program Project Title: Research Fellowship in the Center for Molecular Oncologic Pathology (CMOP). / Source of Funding: Industry: Nuclea Biomarkers, LLC 2009 Lance Ostrom / Dr. Loda served as Mr. Ostrom’s thesis advisor at Harvard Extension School Thesis title: “Relevance of sample handling in the assessment of PI3K activated targets in prostate cancer 2009-2010 Michelangelo Fiorentino, M.D., Ph.D. / Director of the laboratory of oncologic molecular pathology S.Orsola-Malpighi Hospital, Bologna, Italy. Title: Associate Director for the Center for Molecular Oncologic Pathology (CMOP), Dana-Farber Cancer Institute/Brigham and Women’s Hospital 2009-2013 Natalia Scaglia, Ph.D. / Assistant Professor, The Biochemistry Research Institute of La Plata (INIBIOLP) Project Title: Fatty acid metabolism during the cell cycle 2009-2012 Saumyadipta Pyne, Ph.D. / Resarch Scientist, Dana-Farber Cancer Institute, Boston, MA Project Title: Fatty acid synthase and prostate cancer 2010-2011 Emma Cashman, M.D., Ph.D. / Resident, Surgical Otolaryngology, St. James Hospital. Dublin, Ireland Project title: The cause and consequence of centrosome and ploidy abnormalities in human cancers using barrett’s Esophagus as a model; DNA methylaion of histones 1996 -2011 Michael Murphy, M.B. / Professor of Dermatology and Dermatopathology, University of Connecticut 2010 - 2014 Stefano Sioletic, M.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA Project title: Phamacodynamic profiling 2010 - 2015 Debora Bastos, Ph.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA 19 Loda - CV Project title: Genetic crosses of Pten and Fasn knock out mice 2011 – 2013 Silvio Marques Zanata, M.D., Ph.D. / Associate Professor, Department of Basic Pathology, Federal University of Paraná, Brazil Project Title: Integrative models to define metabolic signatures in human prostate tumors: toward new antimetabolic approaches in cancer therapeutics. 2015 - present Nelma Gomes, Ph.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA Project Title: Define the metabolic signature predictive of metastasis in prostate tumors driven by AKT/MYC alterations Formally Supervised Genito-Urinary Pathology Fellows 2001-2002 Junyi Lei, M.D. / Anatomic Pathology & Clinical Pathology, Jdxpath Inc., Collegeville, PA Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2007-2008 Juan Miguel Mosquera, M.D., M.Sc. / Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2007-2008 Saleem Umar, M.D. / Cytopathologist, Cleveland, OH Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2010-2011 Christopher Davidson, M.D. / Queen’s University, Ontario Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2009-2012 Marcela Riveros-Angel, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2011-2012 Trevor Flood, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital 2013-present Elizabeth Kehr, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women’s Hospital Formal Teaching of Peers (e.g., Continuing Medical Education and other continuing education courses) Formal Teaching of Peers 1991 Continuing medical education course, Director USL, Imola, Italy “Molecuar biology applied to anatomic pathology” CME Course 1995 Continuing medical education course, Faculty Florence, Italy. “Molecular pathology and cytometry” CME Course 1996 Harvard Medical School course. Modern Surgical Oncology. Boston, MA “What the surgeon needs to know about breast cancer pathology” CME Course 1996 Course on “Automation in immunohistochemistry and in situ hybridization” Treviso, Italy. Lectures: 1) In situ hybridization: principles and applications; 2) Expression and function of MAP kinase phosphatase in epithelial carcinogenesis; 3) Differential display-PCR-in situ Invited faculty. Lecturer 20 Loda - CV hybridization: a new method in the assessment of novel genes. 1996 Universidade Federal de Sao Paulo, Brazil. Postgraduate course in Anatomic Pathology. Invited faculty. Lecturer Lecture 1 “Applications of molecular biology to diagnostic pathology: clinical and prognostic significance”; lecture 2: “Oncogenes and cancer: role of cyclin kinase inhibitor p27 in carcinogenesis”; lecture 3:” The MAP kinase pathway in epithelial carcinogenesis”; lecture 4: “Hepatitis C: reverse transcriptase-PCR assays in transplant patients” 2008 Udine University, Italy: Four day Course in Molecular Pathology to the graduate program, Director D. Claudio Brancolini. Lectures in Udine, Trieste, Aviano, Italy Invited faculty. Lecturer 2009 Biology of Cancer course: Johns Hopkins University School of Medicine and Sidney Kimmel Cancer Center, Baltimore, M.D. “Metabolism in cancer pathogenesis and maintenance” Invited speaker and meeting with graduate students Invited speaker 2010 Clinical Pathology CME Course, Department of Pathology, Brigham and Women’s Hospital Lecture topic: “Metabolic Dysregulation in Cancer and Metabolic Syndrome” Invited Speaker Report of Regional, National and International Invited Teaching and Presentations Invited Presentations and Courses Regional Invited Presentations Those presentations below sponsored by outside entities are so noted and the sponsor is identified. 1991 “Gsp point mutation in thyroid tumors” Seminar Adriatic Society of Pathology, Grado, Italy “Expression of p53 gene in medulloblastoma. A study with quantitative PCR” Seminar Speaker 1991 Immunohistochemistry and molecular biology of pituitary adenomas symposium USL 29 Bologna Ospedale Bellaria. “Diagnostic and therapeutic innovations in pituitary adenomas” Symposium speaker 1992 Lahey Clinical Medical Center Seminar Series Lahey Clinical Medical Center “Applications of molecular biology to diagnostic pathology. Clinical and prognostic signficance" Seminar speaker speaker 1992 Hospital Pathology Departments. “Molecular genetics of medulloblastoma” Deaconess/Brigham & Women's/Beth Israel Hospitals. Seminar speaker 1992 Pathology Grand Rounds. Tufts/New England Medical Center "Molecular genetics of medulloblastoma." Grand Rounds 1995 Immuno/in situ Surgical Pathology Symposium VA Medical Center, Philadelphia, PA.. "Riboprobe in situ hybridization on paraffin embedded tissue: from research to clinical applications" Symposium Speaker 1995 Poster presented at Gordon Conference on Hormonal Carcinogenesis New London, NH. "Mitogen activated protein kinase phosphatase (MKP-1) expression in human prostate Poster Presentation 21 Loda - CV cancer" 1995 Urologic Oncology Conference, Dana Farber Cancer Institute Boston, MA "The role of MAP Kinase phosphatase (MKP-1) in the progression of prostate cancer" Symposium Speaker 1995 Massachusetts General Hospital Pathology Research Seminar Boston, MA "Molecular in situ hybridization: methods and applications" Seminar Speaker 1995 Dana Farber Cancer Institute/Harvard Medical School: Prostate Cancer Retreat. "Mitogen activated protein kinase phosphatase (MKP-1) and apoptosis in prostate cancer” Seminar Speaker 1995 Dana Farber Cancer Institute/Harvard Medical School: Prostate Cancer Retreat. "Mitogen activated protein kinase phosphatase (MKP-1) and apoptosis in prostate cancer” Seminar Speaker 1996 Surgical Grand Rounds Invited speaker Mount Auburn Hospital, Cambridge, MA. “What the surgeon needs to know about breast cancer pathology” Grand Rounds 1996 Mitotix Inc, Cambridge, MA “Translational molecular medicine: cell cycle genes and prognosis in human tumors” Invited speaker 1996 Visiting Professor Lecture Series University of Ancona, Ancona, Italy. Lecture: "Molecular Pathology: recent acquisitions" Invited Lecturer 1997 Yale University, Department of Pathology, Grand rounds “Role of p27 in neoplastic progression” Grand Rounds 1997 New England Society of Pathology. Museum of Science, Boston, MA “Molecular diagnostic and prognostic markers of disease” Invited speaker 1997 Massachusetts General Hospital. Grand Rounds “Role of p27 in epithelial carcinogenesis” Grand Rounds 1998 Combined Pathology Grand Rounds. Harvard Medical School, Boston, MA “Role of p27 in epithelial carcinogenesis” Grand Rounds 1998 University of Massachusetts, Seminars in Surgical Pathology “Targeted proteolysis and p27 regulation in epithelial carcinogenesis” Seminar Speaker 1998 Gordon Research Conference on Hormonal Carcinogenesis. Kingston, RI Symposium Speaker “Androgen regulation of p27” 1999 Vertex Pharmaceuticals, Cambridge, MA. “Expression of signal transducing kinases in cancer” Invited speaker 2000 New England Society of Pathologists. Location: Beth Israel Deaconess Medical Center, January 18, 2001. “Surgical and molecular pathology of prostate cancer: prognostic implications” Invited Speaker 22 Loda - CV 2001 Millenium Pharmaceuticals. Invited speaker: “Molecular targets at the G1/S transition “p27 and cdc25A” Invited Speaker 2002 Research Highlights Seminar Series Brigham & Women’s Hospital, Boston, MA “Role of the de-ubiquitinating enzyme USP2 in prostate cancer” Seminar Speaker 2002 Cell Biology Seminar. University of. Massachusetts Medical Center, Worcester, MA “Prostate Cancer Progression: role of Skp2/p27 and of the isopeptidase USP2” Invited Speaker 2002 "Tissue-based Molecular Pathology Technology Workshop". Seminar Series Massachusetts General Hospital Charlestown, Boston MA “In Situ Hybridization, Technology & Application” and “Laser-Capture Microdissection: in Prostate Cancer Research” Invited Speaker 2002 Pathology Grand Rounds. Massachusetts General Hospital, Boston, MA “The isopeptidase USP2 in prostate cancer” Grand Rounds 2003 Experimental Models of Genito-Urinary Cancers Harvard Medical School, Boston, MA Current technologies for disease evaluation – Tissue based molecular pathology technology workshop Invited Speaker 2003 Symposium on Advances and strategies in Molecular Pathology and Target discovery. Boston, MA. “Automated in situ hybridization in Molecular Pathology” Invited Speaker 2004 Carolyn Frye-Halloran Symposium in Neuro-Oncology: Primary CNS Lymphoma: from bench to bedside. Massachusetts General Hospital, Boston, MA “Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection” Invited Speaker 2004 GenPath Pharmaceuticals. Cambridge, MA “Molecular Pathology and drug discovery” Invited Speaker 2004 Merck Pharmaceuticals, Inc. Oncology division. Symposium on metabolism and cancer. Boston, MA “Fatty Acid Synthase as a metabolic oncogene” Invited Speaker 2005 Novartis-Dana Farber Cancer Institute retreat. Sorrento, Italy “Structure and Oncogenic properties of USP2” Invited Speaker 2006 Pathology Grand Rounds. Harvard Medical School, Boston, MA “The isopeptidase USP2a, fatty acid metabolism and cancer” Invited Speaker 2007 Broad Institute. Cambridge, MA “Quantum dot-based in situ gene expression analysis” Invited Speaker 2007 Cell Signaling Technology. Danvers, MA Invited Speaker 23 Loda - CV “Detection of biomarkers in solid tumors: molecular pathology strategies” 2007 Cell Signaling Technology. Danvers, MA “Fatty acid synthase and prostate cancer: in vitro and in vivo models” Invited Speaker 2007 Gene Expression in Tumors Symposium. Children’s Hospital, Boston, MA Symposium Speaker “Quantum dot multiplexed immunohistochemistry /in situ hybridization: a method to determine gene expression profiling in paraffin-embedded tissue” 2007 CRI, Inc., Multiplexed Imaging Workshop, Invited seminar Woburn, MA “Semi-automated multiplexed quantum dot-based in-situ hybridization and spectral deconvolution” Invited Speaker 2007 Millenium, Pharmaceuticals, Inc. Cambridge MA "USP2a and fatty acid synthase: new therapeutic targets in prostate cancer" Invited Speaker 2007 Novartis, Inc. Boston, MA. Novartis Oncology Leadership Team meeting. Invited Speaker 2007 Merck Research Laboratories Boston 2006 Oncology Symposium. Boston, MA Lecture: “Molecular characterization of human tumors” Invited Lecturer 2007 University of Massachusetts Seminar Series Boston, MA. “Oncogenic mechanisms and regulation of fatty acid synthase in prostate cancer”, Invited Lecturer 2008 Gastrointestinal Malignancies Retreat Dana-Farber/Harvard Cancer Center, Boston, MA “Orthotopic xenographs and culturing of tissue sections ex vivo” Invited Speaker 2008 Breast Spore Meeting - Dana-Farber Cancer Institute “Identification and characterization of putative breast cancer stem cells in situ using quantum dot-conjugated antibodies” Invited Speaker 2008 Infinity Pharmaceuticals, Cambridge, MA “Fatty Acid Synthase as a metabolic oncogene in prostate cancer” Invited Speaker 2008 Tri-Institutional Prostate Cancer Program Retreat, Newport, RI Participant/Presenter, Session IV, Prognostic and Predictive Markers Moderator. Invited Speaker 2008 Novartis Retreat, NIBR Oncology and DFCI Joint Retreat Chatham, MA. Prostate Cancer Foundation. Invited Attendee 2008 American Association for Cancer Research (AACR) Targeting the PI3-Kinase Pathway in Cancer Research. Special Conference Cambridge, MA Invited Speaker 24 Loda - CV “Quantitative Tissue Analysis of Activation of the P13K Pathway” 2009 DF/HCC Interdisciplinary Workshop, Incorporating novel tumor tissue analysis into population-based studies of human cancer Dana-Farber/Harvard Cancer Center “Automated scanning and imaging technologies” Invited Speaker 2010 Cell Signalling Technology. Danvers, MA “Development of a PI3K signature in prostate cancer” Invited speaker with Neil Martin, M.D.; May 2010 Invited Speaker 2010 Clinical Pathology Conference series, Pathology Department Brigham & Women’s Hospital “Metabolic dysregulation in cancer and the metabolic syndrome” Invited Speaker 2010 3rd Annual Cancer Symposium, “Prostate Cancer and the Molecular Genetics of Cancer” Beth Israel Deaconess Medical Center “Fatty Acid Synthase as a Metabolic Oncogene in Prostate Cancer” Invited Speaker 2010 NIBR Oncology and Dana Farber Cancer Institute Joint Retreat Braseltone, GA PKPD session, Lecture: “Ex vivo organotypic culture as a tool to determine drug efficacy” Invited Speaker 2010 AACR Workshop on “Translational Cancer Research for Basic Scientists” Panel on Introduction to Cancer Medicine and Diagnostics (R. Weinberg, MIT and M. Loda, DFCI). Lecture topic: “Clinical Pathology and Tissue Diagnosis” Invited Speaker 2011 New England Society of Pathologists, Inc. Royal Sonesta Hotel, Cambridge, MA Hubert J. Wolfe Memorial Lecture: “Metabolic Alterations in Prostate Cancer” Invited Speaker 2011 Agios Pharmaceuticals Conference. Cambridge, MA “Metabolic Syndrome, AMPK and the lipogenic phenotype in prostate cancer” Invited Speaker; July 6, 2011 Invited Speaker 2011-2014 AACR Workshop on “Translational Research for Basic Scientists” Panel Discussion on Personalized Cancer Medicine and What It Means in the Clinic Lecture Topic: “Diagnostic Pathology: A Primer” October 31, 2011 Invited Faculty Lecturer 2014 Massachusetts General Hospital Pathology Department Grand Rounds "Metabolic dependencies in prostate cancer: regulation and targeting of lipogenesis” Invited Speaker National Invited Presentations Those presentations below sponsored by outside entities are so noted and the sponsor is identified. 1996 Department of Pathology, New York Invited speaker 25 Loda - CV New York University, Department of Pathology, New York "Role of MKP-1 in the progression of prostate cancer" 1996 Albert Einstein Medical Center, Philadelphia, PA. "Riboprobe in situ hybridization: principles and applications" Invited speaker 1997 University of Chicago, Department of Pathology Chicago, IL “Role of p27 in epithelial carcinogenesis” Invited Speaker 1997 Department of Pathology. Molecular Pathology Grand Rounds University of Pittsburgh Medical Center, Pittsburgh, PA “Role of p27 in epithelial carcinogenesis” Invited Speaker 1997 University of California Los Angeles, Department of Pathology Los Angeles, CA “Role of p27 in epithelial carcinogenesis” Invited Speaker 1998 Kaplan Comprehensive Cancer Center, Breast Cancer Research Seminar New York University, New York, NY “Role of cyclin dependent kinase inhibitor p27 in breast cancer” Invited Speaker 1998 Fred Hutchinson Cancer Center and Department of Pathology University of Washington, Seattle, WA “The cell cycle inhibitor p27: prognosis and regulation” Invited Speaker 1998 The Vollum Institute, Oregon Health Sciences University, Portland, Oregon. “The cell cycle inhibitor p27: prognosis and regulation” Invited Speaker 1999 Memorial Sloan Kettering Cancer Center, Society for applied immunohistochemistry. New York, NY “In situ hybridization: an update” Invited Speaker 2001 New York University, Department of Pathology. “Role and regulation of the cell cycle inhibitor p27 in normal and neoplastic prostate”. Invited Speaker 2002 M.D. Anderson Cancer Center, Houston Texas. Grand rounds, Dept. of Pathology: “Molecular determinants of prostate cancer progression”. Grand Rounds 2002 Distinguished Visitor Seminar Series. Univ of Kentucky, Lexington, KY. “Molecular determinants of prostate cancer progression” Invited Speaker 2003 American Society for Investigative Pathology. (FASEB) San Diego, CA “Pathobiology for basic scientists, Growth and development: signaling and repair mechanisms regulating growth, development and disease” Invited Speaker for Course 2003 New York University, Department of Pathology seminar series; “Molecular pathology: towards probes of cell function in tumors” Invited Speaker 2004 Third International Symposium on genitourinary cancers. Chair Nicholas J Vogelzang, Santa Barbara, CA. “Renal cancers: Pathology” and “Prostate cancer: Pathology and Molecular Prognostics” Invited Speaker 26 Loda - CV 2004 Department of Pathology/UCSF Cancer Center University of California, San Francisco. “USP2a regulates the stability of Fatty Acid Synthase in Prostate Cancer” Invited Speaker 2004 Seminar series, Department of Pathology University of Michigan, Ann Arbor. “USP2a regulates the stability of Fatty Acid Synthase in Prostate Cancer” Invited Speaker 2005 Symposium on “Molecular Pathology of Neoplasia” The New York Pathological Society, Brooklyn, NY “Molecular Pathology of Murine and Human Prostate Cancer” Invited Speaker 2005 Berlex Pharmaceuticals. Montville, NJ “USP2a is an oncogenic isopeptidase” Invited Speaker 2007 Prostate Cancer Inter-SPORE Meeting. Chair, session on Biomarkers in Prostate Cancer. Symposium chair 2007 Prostate Program Investigator’s Meeting. Dan. L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX “The isopeptidase USP2a fatty acid synthase and prostate carcinogenesis” Invited Speaker 2007 Case Western Reserve University (CWRU) Seminar Series Cleveland, OH “USP2a is an oncogenic isopeptidase in prostate cancer” Invited Speaker 2007 Molecular Devices Corporation, Seminar Sunnyvale, CA “Semi-automated multiplexed quantum dot based in-situ hybridization and spectral deconvolution” Invited Speaker 2007 Mayo Clinic Seminar, Rochester MN "Fatty acid Synthase as a metabolic oncogene in prostate cancer” Invited Speaker 2007 Starr Cancer Consortium Workshop. New York, NY. Chair of Molecular Pathology Session Symposium Chair 2007 Department of Cancer Biology Wake Forest University School of Medicine, Winston-Salem, NC “Fatty Acid Synthase as a metabolic oncogene in prostate cancer” Invited Speaker 2008 University of Pittsburgh Medical Center Seminar “Fatty acid synthase as a metabolic oncogene in prostate cancer” Invited Speaker 2008 Cancer Stem Cell Workshop, Session Chair entitled “Methods to Identify CSCs in Clinical Specimens” NCI, Bethesda, MD “Detection of CSC by multiplex spectral imaging” Session Chair and Invited Speaker 27 Loda - CV 2008 External Consultant, Cancer Biology Faculty Departmental Retreat Wake Forest University Health Sciences, director Dr Steven Akman, August 2008 Winston-Salem, NC “Role of USP2a in the EGFR endocytic pathway” Guest reviewer and Invited Speaker 2008 New York University, Department of Pathology seminar series; “Fatty Acid Synthase as a metabolic oncogene in prostate cancer” Invited Speaker 2008 American Association for Cancer Research (AACR) Targeting the PI3-Kinase Pathway in Cancer Research. Special Conference. Cambridge, MA “Quantitative Tissue Analysis of Activation of the P13K Pathway” Invited Speaker 2009 UCLA Prostate Cancer SPORE, Annual Advisory Board Mtg Keynote Speaker Los Angeles, CA “Metabolism in cancer pathogenesis and maintenance” Keynote Speaker 2009 Biology of Cancer course: Johns Hopkins University School of Medicine and Sidney Kimmel Cancer Center, Baltimore, M.D. “Metabolism in cancer pathogenesis and maintenance” Invited speaker and meeting with graduate students Invited speaker 2009 American Society of Clinical Oncology (ASCO) ASCO session in Orlando Florida Chair, session, Targeting ubiquitin and ubiquitin-like modifier pathways Chair and Invited speaker 2010 Prostate Inter-SPORE meeting Ft Lauderdale, Florida, April 2010 Co-chair of Session V—Prognostic and Predictive Markers and Session VI – Pathology standardization Chair and Invited speaker 2010 American Urologic Association (AUA), San Francisco, CA Chair of session on “Inflammation and Urologic Diseases” Invited Speaker 2010 Genentech, Inc. San Francisco, CA “Metabolic targets in prostate cancer” Invited Speaker Genentech 2010 Massachusetts General Hospital-Brigham and Women’s Hospital Partners Integrated Molecular Pathology Retreat. Belmont, MA Co-director, MGH-BWH Partners Integrated Molecular Pathology of Cancer Retreat, Invited Speaker and Co-director 2010 Tumor Microenvironment Network, NCI. Bethesda, MD “Metabolic Alterations in Prostate Cancer” Invited Speaker 2010 AACR Workshop on “Translational Cancer Research for Basic Scientists” Panel on Introduction to Cancer Medicine and Diagnostics (R. Weinberg, MIT and M. Loda, DFCI). Lecture topic: “Clinical Pathology and Tissue Diagnosis” Invited Speaker 2011 35th annual Lineberger Cancer Center symposium on cell metabolism and cancer” University of North Carolina - Chapel Hill, NC Invited Speaker 28 Loda - CV Lecture topic: “Cell Metabolism and Cancer” 2011 M.D. Anderson Cancer Center, Houston Texas. Grand rounds, Dept. of Pathology: “Metabolic Alterations in Prostate Cancer.” Grand Rounds 2011 The Italian Genius and the World Industrial Development Italian Cultural Institute – New York City, NY, Dec 6, 2011 Lecture topic: “From Golgi to Levi Montalcini, The Italian Contribution to the Revolution in Life Sciences” Invited Speaker 2011 UCSF Urologic Oncology Research Seminar. San Francisco, CA, “Metabolic Alterations in Prostate Cancer” Invited Speaker Fall 2011 18th Annual Prostate Cancer Foundation, Session on Metabolic alterations in prostate cancer. Lake Tahoe, Nevada “ Metabolic Alterations in Prostate Cancer” 2012 The Vollum Institute, Oregon Health Sciences University, Portland, Oregon. “Metabolic Alterations in Prostate Cancer” Invited Speaker 2012 Department of Pathology, MD Anderson Cancer Center, Houston, TX. “Metabolic Alterations in Prostate Cancer: The Lipogenic Phenotype” Invited Speaker 2013 Department of Pathology, New York University Langone Medical Center, New York, NY. “Metabolic Alterations in Prostate Cancer” Invited Speaker 2013 Metabolism and Cancer Symposium, Mayo Clinic, Rochester, MN “Metabolic Profiling in Prostate Cancer” Invited Speaker 2013 Purdue University Center for Cancer Research Seminar Series, West Lafayette, IN. “Lipogenesis in prostate cancer: oncogenic drivers and therapeutic targets” Invited Speaker 2014 4th Annual GU Research Retreat, Roswell Park Cancer Institute, Buffalo, NY “Targeting the lipogenic phenotype in prostate cancer” Invited Speaker 2014 7th Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL Invited Speaker 2014 The New York Academy of Sciences: Companion Diagnostics: From Biomarker Identification to Market Entry “Innovation in Metabolomics to Improve Personalized Healthcare” Invited Speaker 2014 Prostate Caancer Working Group and Journal Club, Cleveland Clinic, Cleveland, OH “Metabolic Dependencies in Prostate Cancer: Regulation and Targeting of Lipgenesis” Invited Speaker 2015 8th Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL Invited Speaker 2015 AACR Annual Meeting – Meet the Experts Philadelphia, PA "Molecular Pathoogy in Oncology” Invited Speaker 29 Invited Speaker and Chair Loda - CV International Invited Presentations No presentations below were sponsored by outside entities 1998 University of Bologna, Inauguration of New Cancer Center “p27: prognostic role and regulatory pathways” Invited Speaker 1999 Sunnybrook & Women’s College Health Sciences Center, Ontario. Division of Cancer Biology Research Seminar Series. Ontario, Canada “p27 and cdc25: prognostic significance and regulation in solid tumors” Seminar Speaker 2000 Genito-Urinary Pathology, United States and Canadian Academy of Pathology, New Orleans, LA Chair, proferred papers session Chair and Speaker 2003 Italian Society of Medical Oncology, Rome, Italy. “Molecular Pathology of Prostate Cancer” Invited Speaker 2004 Symposium on Tissue Microarrays. Milan, Italy. “Tissue microarrays versus gene expression profiling” Invited Speaker 2004 Prostate Cancer Foundation, Santa Monica, CA “Fatty Acid Synthase: a metabolic oncogene in prostate cancer” Invited Speaker 2007 American Association for Cancer Research (AACR) Aspen, Colorado. Faculty, AACR course “Molecular Biology in Clinical Oncology” Invited Faculty 2008 Universita’ Vita e Salute, San Raffaelle Hospital, Milan Italy “Fatty Acid Synthase as a Metabolic Oncogene”. Invited Speaker 2008 Prostate Cancer Foundation, Fifteenth Annual Scientific Retreat Lake Tahoe, Nevada Invited Speaker 2009-2013 Course co-director with David Berman, M.D., Ph.D. United States and Canadian Academy of Pathology, USCAP “Careers in investigative pathology: the road less traveled”. Course codirector 2009 Prostate Cancer Foundation, Session on Metabolic alterations in prostate cancer Lake Tahoe, Nevada Invited Speaker and Chair 2010 Molecular Pathology Course, 26th Annual Scientific Conference. The Egyptian Society of Anesthesiologists. Cairo, Egypt, April 2010. Four invited lectures: “Techniques in Molecular Pathology: Genome-wide analyses”; “Survey of molecular techniques applied to pathology specimens”; “Use of biomarkers in clinical trials with targeted agents”; “Molecular analysis of prostate cancer” Invited Speaker 2011 Gaelic Patho-Epidemiology Retreat, Dublin, Ireland Invited Speaker and coordinator 2011 Center for Cancer Biology, Center for Molecular Oncology and Illumina Next-Generation Sequencing Symposium “Molecular Pathology and advanced genomics: challenges and opportunities” Invited Speaker 2011-2016 23rd Pezcoller Symposium, Member of the Scientific Advisory Board, 5-year term Trento, Italy 30 Invited Speaker and organizer Loda - CV 2011 Presentation at the Italian Cultural Institute, New York, NY, for 150th anniversary of the reunification of Italy Lecture topic: Camillo Golgi. “From Golgi to Levi Montalcini, The Italian Contribution to the Revolution in Life Sciences” Invited Speaker 2012 Prostate Cancer Symposium, Belfast, Ireland “ Metabolic Alterations in Prostate Cancer” Invited Speaker 2013 Transdisciplinary Prostate Cancer Partnership, Gullmarsstrand, Sweden Annual Retreat and Steering Committee Meeting Committee Reviewer 2013 1st International Conference on Oncology and Anticancer Research – 4th International Conference on Recent Advances in Heath and Medical Sciences – 22nd International Conference on Chelation. Pahpos, Cyprus "AKT1 and MYC: Distinctive Metabolic Fingerprints in Prostate Cancer” Invited Speaker 2014 Oslo Prostate Cancer Symposium – From the Bench to the Clinic Oslo, Norway "Targeting the lipogenic phenotype in prostate cancer” 2014 Insitiuto Scientificio San Raffaele- Plenary Lecture Milan, Italy "Lipogenic prostate cancers: link to the metabolic syndrome and therapeutic opportunities” 2015 Oslo Prostate Cancer Symposium Oslo, Norway "Metabolic dependencies in prostate cacner; regulation and targeting of lipogenesis” 2015 Brazilian Biochemistry and Molecular Biology Meeting Foz do Iguacu, Brazil "Metaboloic dependencies in prostate cancer: regulation and targeting of lipogenesis” 2015 School of Dentistry of the State University of Campinas (UNICAMP) Biracicaba, Brazil "Metaboloic dependencies in prostate cancer” 2015 Journal do Programa de Oncobiologia Rio de Jainero, Brazil “Metabolic dependencies in prostate cancer. Update on prostate cancer TCGA” Invited Speaker Invited Speaker Invited Speaker Invited Speaker Invited Speaker 31 Invited Speaker Loda - CV Report of Clinical Activities and Innovations Current Licensure and Certification 1980 1981 1985 1985 1986 1988 1989 State licensure examination, Italy ECFMG examination FMGEMS examination Boards in Emergency Surgery, Italy FLEX examination Massachusetts Medical License American Board of Anatomic Pathology (renewed in 2013 until 2024) Practice Activities Type of Activity Surgical Pathology with a major area of focus of Genito-urinary pathology; Staff Pathologist and director (2007-2010) of the Genitourinary pathology service Setting of Practice Teaching Hosptial Name and Location of Practice Brigham & Women’s Hospital Level of Activity High volume of cases with a high degree of complexity Type of Activity Sign out Molecular Pathology Setting of Practice Teaching Hosptial Name and Location of Practice Brigham & Women’s Hospital Level of Activity High volume of cases with a high degree of complexity Type of Activity Sign out GU Setting of Practice Teaching Hosptial Name and Location of Practice Brigham & Women’s Hospital Level of Activity High volume of cases with a high degree of complexity Clinical Innovations As Director of the Diagnostic Molecular Pathology Laboratory at the New England Deaconess Hospital for several years, one of the goals was to develop new molecular-based, clinically useful tests. To this end I have developed: 1. an RT-PCR based test for the detection of HCV in serum of liver transplant patients (Loda et al, Diag Molec Pathol 1996; 5: 81-87) which was extensively used at my Institution at the time; and 2. a microdissection-T-cell receptor gene rearrangement for cutaneous T-cell lymphomas [Signoretti et al (Am J. Pathol. 1999; 154: 67-75)], also extensively used in routine clinical practice. 3. We were the first to describe the lack of expression of p63 in prostatic adenocarcinomas (Signoretti et al. Am J Pathol 157: 1769-75, 2000). A patent has been obtained (Cell regulatory genes, encoded products, and uses related thereto US 6946256 B1, September 20, 2005). Currently, most laboratories around the country and indeed in the world are utilizing p63 immunohistochemistry as a diagnostic test (lack of p63 expression in cancer) for prostatic adenocarcinomas. 4. We have royalty privileges for developing the colon-specific anti-cdx2 antibody together with Dr. Eric Fearon (Univ. of Michigan and Biogenex, Inc). This is now being used as a marker of colonic origin in metastatic adenocarcinomas of unknown primary. 5. We discovered that metabolic profiles measured by mass spectrometry are specific to human prostate tumors driven by specific oncogenes. Specifically, we can identify Akt1 and Myc status in a prostate tumor by performing an assay to measure a profile of 30 metabolites in a prostate tumor samples (or possibly serum) obtained from prostate cancer patients. A patent has been filed (2013) and a manuscript in in preparation. 6. We discovered that metabolic profiles of biological samples (tissue and blood), are associated with the degree of differentiation in human prostate cancer, and can be used to detect unidentified high grade tumor, allowing the 32 Loda - CV differentiation of aggressive from indolent tumors and enhancing risk prediction in Gleason 7 patients. Metabolic profiling in serum could therefore supplement Gleason score evaluation of a Gleason score 7 prostate tumor by obtaining a biological sample of a subject, measuring a profile of metabolites in the biological sample, and classifying the profile of the metabolites to assign a supplemental Gleason grade to the sample based on the profile of the metabolites. In addition, finding the putative occult Gleason grade 4 and above, missed on biopsy, could alter management of prostate cancer patients. A patent has been filed (2013) and a manuscript in in preparation. 7. I now direct the Center for Molecular Oncologic Pathology at the Dana Farber Cancer Institute/Brigham & Women’s Hospital. In this facility we design novel molecular technologies that are subsequently transferred in the diagnostic arena for application in diagnostic molecular pathology laboratories. As an example, we devised an ex vivo, reproducible, rapid and personalized culture method to investigate antitumoral pharmacological properties that preserves the original cancer microenvironment. Response to signal transduction inhibitors in cancer is determined not only by properties of the drug target but also by mutations in other signaling molecules and the tumor microenvironment. My group in collaboration with Dr. Bosari’s group at the University of Milan, Italy, has shown that this culture model preserves tissue 3D architecture, cell viability, pathway activity, and global gene expression profiles up to 5 days ex vivo. In addition, we show pathway modulation in tumor cells resulting from pharmacologic intervention in ex vivo culture. This technology may have a significant impact on patient selection for clinical trials and in predicting response to small-molecule inhibitor therapy. (Vaira et al, Proc Natl Acad Sci U S A. 2010;107(18):8352-6.). Report of Technological and Other Scientific Innovations Patents Pagano M, Draetta G, Rolfe M, Loda M, inventors; Reagents and methods for diagnosis and prognosis of proliferative disorders. US patent 8,893,276, 1997 Jul 15. McKeon F, Yang A, Loda M, Signoretti S, Crum C. p63 expression pattern in the classification of malignancies of the prostate, cervix and breast. DFCI#700.02 . Yang, A, McKeon F, Signoretti S, Crum C, Loda M. Cell regulatory genes, encoded proteins, and used related thereto. DFCI#700.01 File # HMV-038.02. US 6946256 B1, September 20, 2005 Penney KL, Tyekucheva S., Loda, M,. Metabolic profiling in tissue and serum in indicative of tumor differentiation in prostate cancer. DFCI#1650.02. Priolo C, Tyekucheva S., Loda, M,. Metabolic profiling defines oncogenes driving prostate tumors. DFCI#1613.02. Report of Scholarship Publications * * * Peer reviewed publications in print or other media 1. Loda M, Clowes GHA Jr, Dinarello CA, George BC, Lane B. Induction of accelerated hepatic protein synthesis by a circulating peptide isolated from the plasma of septic patients. Surg Forum 1983; XXXIV:148-51. 2. Loda M, Clowes GH Jr, Nespoli A, Bigatello L, Birkett DH, Menzoian JO. Encephalopathy, oxygen consumption, visceral amino acid clearance, and mortality in cirrhotic surgical patients. Am J Surg. 1984 Apr; 147 (4) :542-50. PubMed PMID:6424488. 3. Loda M, Clowes GH Jr, Dinarello CA, George BC, Lane B, Richardson W. Induction of hepatic protein synthesis by a peptide in blood plasma of patients with sepsis and trauma. Surgery. 1984 Aug; 96 (2) :204-13. PubMed PMID:6611596. 4. Clowes GH Jr, McDermott WV, Williams LF, Loda M, Menzoian JO, Pearl R. Amino acid clearance and prognosis in surgical patients with cirrhosis. Surgery. 1984 Oct; 96 (4) :675-85. PubMed PMID:6484809. 5. Devereux DF, Redgrave TG, Loda MF, Clowes GH Jr, Deckers PJ. Tumor-associated metabolism in the rat is a unique physiologic entity. J Surg Res. 1985 Feb; 38 (2) :149-53. PubMed PMID:3881627. 6. Pearl RH, Clowes GH Jr, Hirsch EF, Loda M, Grindlinger GA, Wolfort S. Prognosis and survival as determined by visceral amino acid clearance in severe trauma. J Trauma. 1985 Aug; 25 (8) :777-83. PubMed PMID:4020912. 33 Loda - CV 7. 8. 9. 10. * 11. 12. * 13. 14. 15. 16. 17. * 18. 19. * 20. 21. 22. * 23. 24. 25. 26. 27. 28. 29. 30. Pearl R, Clowes GHA Jr, Jenkins FL, Loda M, Trey C, Palmer K. Hepatocyte function measured by central plasma clearance of amino acids, a method for patient selection and postoperative management in human liver transplantation. Trans Proc 1985; XVII,1:276-8. Bigatello L, Clowes GHA Jr, Loda M. Effects of amino acid parenteral alimentation on central plasma clearance rates, differentiating survivors and deaths in trauma, sepsis, and gangrene. Surg Forum 1985; XXXVI:3-6. Silverman ML, Loda M, Rossi RL. Malignant tumors of extrahepatic bile ducts. Check Sample 1988; 15(5):1-5. Loda M, Mendoza AE, O'Hara C, Crawford JM, Federman M, Goodman H. Well-differentiated hepatocellular carcinoma associated with long-term survival Report of two cases. Virchows Arch A Pathol Anat Histopathol. 1991; 418 (6) :551-6. PubMed PMID:1711733. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene. 1991 May; 6 (5) :857-62. PubMed PMID:1646989. Lee AK, Wiley B, Loda M, Bosari S, Dugan JM, Hamilton W, Heatley GJ, Cook L, Silverman ML. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol. 1992 Jan; 5 (1) :61-7. PubMed PMID:1347424. Loda M, Giangaspero F, Badiali M, Capodieci P, Pession A. p53 gene expression in medulloblastoma by quantitative polymerase chain reaction. Diagn Mol Pathol. 1992 Mar; 1 (1) :36-44. PubMed PMID:1342953. Lee AK, Wiley B, Dugan JM, Hamilton WH, Loda M, Heatley GJ, Cook L, Silverman ML. Quantitative DNA analysis and proliferation in breast carcinomas A comparison between image analysis and flow cytometry. Pathol Res Pract. 1992 Jun; 188 (4-5) :428-32. PubMed PMID:1329051. Giangaspero F, Rigobello L, Badiali M, Loda M, Andreini L, Basso G, Zorzi F, Montaldi A. Large-cell medulloblastomas A distinct variant with highly aggressive behavior. Am J Surg Pathol. 1992 Jul; 16 (7): 687-93. PubMed PMID:1530108. Badiali M, Iolascon A, Loda M, Scheithauer BW, Basso G, Trentini GP, Giangaspero F. p53 gene mutations in medulloblastoma Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol. 1993 Mar; 2 (1) :23-8. PubMed PMID: 8287222. Fabbretti G, Valenti C, Loda M, Brisigotti M, Cozzutto C, Tonini GP, Callea F. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol. 1993 Mar; 24 (3): 294-7. PubMed PMID: 8454274. Loda M, Fogt F, French FS, Posner M, Cukor B, Aretz HT, Alsaigh N. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol. 1994 Apr; 7 (3): 388-91. PubMed PMID: 8058713. Fogt F, Vortmeyer AO, Ahn G, De Girolami U, Hunt RB, Daly T, Loda M. Neural cyst of the ovary with central nervous system microvasculature. Histopathology. 1994 May; 24 (5): 477-80. PubMed PMID: 8088721. Loda M. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Hum Pathol. 1994 Jun; 25 (6):564-71. PubMed PMID: 7912220. Florio T, Rim C, Hershberger RE, Loda M, Stork PJ. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol. 1994 Oct; 8 (10):1289-97. PubMed PMID: 7854346. Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol. 1994 Oct; 25 (10):1050-6. PubMed PMID: 7927309. Gordon FD, Anastopoulos H, Khettry U, Loda M, Jenkins RL, Lewis WD, Trey C. Hepatitis C infection: a rare cause of fulminant hepatic failure. Am J Gastroenterol. 1995 Jan; 90 (1):117-20. PubMed PMID: 7801910. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995 Aug 15; 55 (16):3509-12. PubMed PMID: 7627956. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, Summerhayes IC. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene. 1995 Aug 17; 11 (4):647-52. PubMed PMID: 7651727. Yao H, Labudda K, Rim C, Capodieci P, Loda M, Stork PJ. Cyclic adenosine monophosphate can convert epidermal growth factor into a differentiating factor in neuronal cells. J Biol Chem. 1995 Sep 1; 270 (35):20748-53. PubMed PMID: 7657657. Fogt F, Capodieci P, Loda M. Assessment of perineural invasion by GLUT-1 immuno-histochemistry. Appl Immunohisto 1995; 3:194-7. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25 phosphatases as potential human oncogenes. Science. 1995 Sep 15; 269 (5230):1575-7. PubMed PMID: 7667636. Jessup JM, Lavin PT, Andrews CW Jr, Loda M, Mercurio A, Minsky BD, Mies C, Cukor B, Bleday R, Steele G Jr. Sucraseisomaltase is an independent prognostic marker for colorectal carcinoma. Dis Colon Rectum. 1995 Dec; 38 (12):1257-64. PubMed PMID: 7497836. Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M, Bevilacqua G, Coggi G. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol. 1995 Dec; 4 (4):249-55. PubMed PMID: 8634780. 34 Loda - CV 31. 32. * 33. 34. * 35. 36. 37. 38. * 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996 Feb 1; 77 (3):490-8. PubMed PMID: 8630956. Loda M, Fiorentino M, Meckler J, Khettry U, Lewis D, Washburn K, Jenkins R, Mendoza AE, Samuelson J. Hepatitis C virus reinfection in orthotopic liver transplant patients with or without concomitant hepatitis B infection. Diagn Mol Pathol. 1996 Jun; 5 (2):81-7. PubMed PMID: 8727094. Leav I, Galluzzi CM, Ziar J, Stork PJ, Ho SM, Loda M. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest. 1996 Sep; 75 (3) :361-70. PubMed PMID:8804359. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol. 1996 Nov; 149 (5) :1553-64. PubMed PMID:8909245; PubMed Central PMCID: PMC1865259. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med. 1996 Dec; 2 (12) :1322-8. PubMed PMID:8946830. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M, Summerhayes IC. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996 Dec 5; 335 (23) :1727-32. PubMed PMID:8929264. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest. 1997 Jan; 76 (1) :37-51. PubMed PMID:9010448. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb; 3 (2) :2314. PubMed PMID:9018245. Lee AK, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. Cancer. 1997 Feb 15; 79 (4) :761-71. PubMed PMID:9024714. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997 Mar 1; 57 (5) :808-11. PubMed PMID:9041175. Lise M, Loda M, Fiorentino M, Mercurio AM, Summerhayes IC, Lavin PT, Jessup JM. Association between sucraseisomaltase and p53 expression in colorectal cancer. Ann Surg Oncol. 1997 Mar; 4 (2) :176-83. PubMed PMID:9084856. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997 Apr 1; 57 (7) :1259-63. PubMed PMID:9102210. Ellis FH Jr, Loda M. Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Dis Esophagus. 1997 Jul; 10 (3) :165-71. PubMed PMID:9280074. Selletti L, Taveggia G, Grioni G, Uggeri M, Loda M, Pastorelli GM. [Principles of a rehabilitation treatment for returning to work after a stabilization intervention with the Colorado method]. G Ital Med Lav Ergon. 1997 Jul-Sep; 19 (3) :76-9. PubMed PMID:9463048. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol. 1997 Aug; 10 (8) :839-45. PubMed PMID:9267828. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15; 57 (16) :3381-5. PubMed PMID:9270000. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998-1999; 17 (4) :337-44. PubMed PMID:10453277. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998 Feb 17; 95 (4) :1735-40. PubMed PMID:9465086; PubMed Central PMCID: PMC19171. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998 Mar; 159 (3) :941-5. PubMed PMID:9474188. Bao L, Loda M, Zetter BR. Thymosin beta15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis. 1998 Apr; 16 (3) :227-33. PubMed PMID:9568640. Capodieci P, Magi-Galluzzi C, Moreira G Jr, Zeheb R, Loda M. Automated in situ hybridization: diagnostic and research applications. Diagn Mol Pathol. 1998 Apr; 7 (2) :69-75. PubMed PMID:9785004. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998 Apr 15; 58 (8) :1730-5. PubMed PMID:9563491. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch. 1998 May; 432 (5) :407-13. PubMed PMID:9645439. 35 Loda - CV 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. * 71. 72. 73. 74. Yang M, Loda M, Sytkowski AJ. Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines. Cancer Res. 1998 Aug 15; 58 (16) :3732-5. PubMed PMID:9721886. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 1998 Sep; 153 (3) :681-7. PubMed PMID:9736017; PubMed Central PMCID: PMC1853015. Magi-Galluzzi C, Murphy M, Cangi MG, Loda M. Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Anal Quant Cytol Histol. 1998 Oct; 20 (5) :343-50. PubMed PMID:9801751. Signoretti S, Murphy M, Cangi MG, Puddu P, Kadin ME, Loda M. Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol. 1999 Jan; 154 (1) :67-75. PubMed PMID:9916920; PubMed Central PMCID: PMC1853445. Sharifi S, Murphy M, Loda M, Pinkus GS, Khettry U. Nodular lymphoid lesion of the liver: an immune-mediated disorder mimicking low-grade malignant lymphoma. Am J Surg Pathol. 1999 Mar; 23 (3) :302-8. PubMed PMID:10078921. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 1999 Mar; 154 (3) :863-70. PubMed PMID:10079264; PubMed Central PMCID: PMC1866401. Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, Zhang J, Liu Y, Qian X, Sutherland R, Magi-Galluzzi C, Weisberg E, Cheng EY, Hao L, Sasaki H, Campbell MS, Kraeft SK, Loda M, Lo KM, Chen LB. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res. 1999 May 1; 59 (9) :2023-8. PubMed PMID:10232579. Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD. P53 and beta catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol. 1999 Aug; 23 (8) :963-9. PubMed PMID:10435567. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999 Sep 1; 59 (17) :4291-6. PubMed PMID:10485474. Walsh S, Murphy M, Silverman M, Odze R, Antonioli D, Goldman H, Loda M. p27 expression in inflammatory bowel disease-associated neoplasia Further evidence of a unique molecular pathogenesis. Am J Pathol. 1999 Nov; 155 (5) :1511-8. PubMed PMID:10550307; PubMed Central PMCID: PMC1866983. Murphy M, Signoretti S, Nasser I, Sherburne B, Loda M. Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. Hum Pathol. 1999 Nov; 30 (11) :1361-6. PubMed PMID:10571518. Signoretti S, Murphy M, Puddu P, DeCoteau JF, Faraggiana T, Kadin ME, Loda M. Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. Diagn Mol Pathol. 1999 Dec; 8 (4) :176-82. PubMed PMID:10617273. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000 Jan; 27 (1) :95-103. PubMed PMID:10564591. Khettry U, Anand N, Gordon FD, Jenkins RL, Tahan SR, Loda M, Lewis WD. Recurrent hepatitis B, hepatitis C, and combined hepatitis B and C in liver allografts: a comparative pathological study. Hum Pathol. 2000 Jan; 31 (1) :101-8. PubMed PMID:10665920. Chiaur DS, Murthy S, Cenciarelli C, Parks W, Loda M, Inghirami G, Demetrick D, Pagano M. Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors. Cytogenet Cell Genet. 2000; 88 (3-4) :255-8. PubMed PMID:10828603. Xu X, LoCicero J 3rd, Macri E, Loda M, Ellis FH Jr. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. J Surg Res. 2000 Feb; 88 (2) :120-4. PubMed PMID:10644476. Loda M, Xu X, Pession A, Vortmeyer A, Giangaspero F. Membranous expression of glucose transporter-1 protein (GLUT1) in embryonal neoplasms of the central nervous system. Neuropathol Appl Neurobiol. 2000 Feb; 26 (1) :91-7. PubMed PMID:10736070. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000 Mar 2; 19 (10) :1288-96. PubMed PMID:10713670. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000 Mar 23; 404 (6776) :407-11. PubMed PMID:10746730. Murphy M, Signoretti S, Kadin ME, Loda M. Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. J Cutan Pathol. 2000 May; 27 (5) :228-34. PubMed PMID:10847547. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G Jr, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep; 106 (6) :753-61. PubMed PMID:10995786; PubMed Central PMCID: PMC381390. 36 Loda - CV 75. * 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000 Oct; 6 (10) :3966-72. PubMed PMID:11051245. Loda M. p27KIP1: androgen regulation and prognostic significance in prostate cancer. Adv Clin Path. 2000 Oct; 4 (4) :22632. PubMed PMID:11436163. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000 Dec; 20 (23) :8969-82. PubMed PMID:11073996; PubMed Central PMCID: PMC86551. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000 Dec; 157 (6) :1769-75. PubMed PMID:11106548; PubMed Central PMCID: PMC1885786. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 6; 92 (23) :1918-25. PubMed PMID:11106683. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275 (50) :39223-30. PubMed PMID:11010972. Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer. 2001 Mar 23; 84 (6) :748-53. PubMed PMID:11259087; PubMed Central PMCID: PMC2363812. Fernández-Santos JM, Utrilla JC, Conde E, Hevia A, Loda M, Martín-Lacave I. Decrease in calcitonin and parathyroid hormone mRNA levels and hormone secretion under long-term hypervitaminosis D3 in rats. Histol Histopathol. 2001 Apr; 16 (2) :407-14. PubMed PMID:11332696. Kulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer. 2001 Apr 15; 91 (8) :1451-7. PubMed PMID:11301392. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M. Androgendriven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001 May; 15 (5) :765-82. PubMed PMID:11328857. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of M.D.m-2 expression. Mod Pathol. 2001 May; 14 (5) :437-42. PubMed PMID:11353054. Sasaki H, Lo KM, Chen LB, Auclair D, Nakashima Y, Moriyama S, Fukai I, Tam C, Loda M, Fujii Y. Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res. 2001 Aug; 92 (8) :869-73. PubMed PMID:11509119. DeSalle LM, Latres E, Lin D, Graner E, Montagnoli A, Baker RT, Pagano M, Loda M. The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein. Oncogene. 2001 Sep 6; 20 (39) :5538-42. PubMed PMID:11571652. Ellis FH Jr, Xu X, Kulke MH, LoCicero J 3rd, Loda M. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg. 2001 Oct; 122 (4) :809-14. PubMed PMID:11581618. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98 (24) :13790-5. PubMed PMID:11707567; PubMed Central PMCID: PMC61120. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001 Dec; 159 (6) :2239-48. PubMed PMID:11733373; PubMed Central PMCID: PMC1850596. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001 Dec 18; 98 (26) :15149-54. PubMed PMID:11742071; PubMed Central PMCID: PMC64998. Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, Merlino G, DePinho RA. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol. 2002 Jan; 22 (2) :635-43. PubMed PMID:11756558; PubMed Central PMCID: PMC139752. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002 Jan 1; 62 (1) :89-98. PubMed PMID:11782364. Oh WK, Loda M, Kantoff PW, Janicek M. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167 (3) :1392. PubMed PMID:11832744. 37 Loda - CV 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar; 1 (2) :203-9. PubMed PMID:12086878. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002 Jun 15; 62 (12) :3485-92. PubMed PMID:12067992. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002 Jul 15; 62 (14) :3925-8. PubMed PMID:12124320. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002 Sep; 110 (5) :633-41. PubMed PMID:12208864; PubMed Central PMCID: PMC151109. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 2002 Sep 12; 419 (6903) :162-7. PubMed PMID:12226664. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem. 2002 Sep 27; 277 (39) :36689-96. PubMed PMID:12095985. Weinstein DA, Roy CN, Fleming M.D., Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002 Nov 15; 100 (10) :377681. PubMed PMID:12393428. Lindeman N, Waltregny D, Signoretti S, Loda M. Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol. 2002 Dec; 11 (4) :187-92. PubMed PMID:12459634. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002 Dec; 15 (12) :1302-8. PubMed PMID:12481011. Osipov V, Keating JT, Faul PN, Loda M, Datta MW. Expression of p27 and VHL in renal tumors. Appl Immunohistochem Mol Morphol. 2002 Dec; 10 (4) :344-50. PubMed PMID:12607603. Fujishita T, Loda M, Turner RE, Gentler M, Kashii T, Breathnach OS, Johnson BE. Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology. 2003; 64 (4) :399-406. PubMed PMID:12759538. Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003 Feb; 27 (2) :141-9. PubMed PMID:12548159. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003 Feb; 77 (3) :245-52. PubMed PMID:12602924. Fleming M.D., Pinkus JL, Fournier MV, Alexander SW, Tam C, Loda M, Sallan SE, Nichols KE, Carpentieri DF, Pinkus GS, Rollins BJ. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003 Apr 1; 101 (7) :2473-5. PubMed PMID:12642342. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003 May-Jun; 9 (3) :208-12. PubMed PMID:12752629. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate. 2003 May 15; 55 (3) :206-18. PubMed PMID:12692787. Kukoski R, Blonigen B, Macri E, Renshaw AA, Hoffman M, Loda M, Datta MW. p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis. Appl Immunohistochem Mol Morphol. 2003 Jun; 11 (2) :138-43. PubMed PMID:12777997. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A. 2003 Jun 24; 100 (13) :7841-6. PubMed PMID:12799464; PubMed Central PMCID: PMC164675. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003 Aug; 1 (10) :707-15. PubMed PMID:12939396. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003 Aug; 1 (10) :765-75. PubMed PMID:12939402. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer 38 Loda - CV 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003 Aug 15; 63 (16) :4781-5. PubMed PMID:12941794. Moreira Júnior G, Colleoni GW, Cangi MG, Murphy M, Sherburne B, Bordin JO, Loda M. Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003 Sep; 12 (3) :128-32. PubMed PMID:12960694. Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem. 2003 Nov 7; 278 (45) :44608-16. PubMed PMID:12947088. Ellis FH Jr, Loda M. p27 and Barrett's esophagus: a review*. Dis Esophagus. 2004; 17 (2) :113-7. PubMed PMID:15230722. Pachori AS, Melo LG, Zhang L, Loda M, Pratt RE, Dzau VJ. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun. 2004 Jan 16; 313 (3) :528-33. PubMed PMID:14697221. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1; 10 (3) :828-39. PubMed PMID:14871958. Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004 Mar; 19 (2) :114-20. PubMed PMID:14634775. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004 Mar; 5 (3) :253-61. PubMed PMID:15050917. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004 Apr 1; 64 (7) :2365-70. PubMed PMID:15059887. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 Jun; 10 (6) :594-601. PubMed PMID:15156201. Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10 (14) :4680-7. PubMed PMID:15269140. Agostini M, Silva SD, Zecchin KG, Coletta RD, Jorge J, Loda M, Graner E. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol. 2004 Aug; 40 (7) :728-35. PubMed PMID:15172643. Murphy M, Carlson JA, Keough MP, Claffey KP, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol. 2004 Aug; 31 (7) :477-82. PubMed PMID:15239677. Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX31 during prostate carcinogenesis. J Urol. 2004 Sep; 172 (3) :1134-9. PubMed PMID:15311057. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2 (9) :48994. PubMed PMID:15383627. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004 Nov; 17 (11) :1392-9. PubMed PMID:15205684. Takahashi C, Contreras B, Bronson RT, Loda M, Ewen ME. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. Mol Cell Biol. 2004 Dec; 24 (23) :10406-15. PubMed PMID:15542848; PubMed Central PMCID: PMC529028. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec; 35 (12) :1462-8. PubMed PMID:15619204. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64 (24) :8867-75. PubMed PMID:15604246. Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M. Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene. 2005 Mar 3; 24 (10) :1683-8. PubMed PMID:15674336. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005 Mar 15; 11 (6) :2237-43. PubMed PMID:15788672. 39 Loda - CV 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Thadhani R, Bonventre JV. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005 Apr; 16 (4) :1126-34. PubMed PMID:15744000; PubMed Central PMCID: PMC1307501. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol. 2005 May; 173 (5) :1772-7. PubMed PMID:15821585. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005 Jun 15; 65 (12) :5054-62. PubMed PMID:15958548. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem. 2005 Jul 1; 280 (26) :25134-45. PubMed PMID:15802273. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005 Jul 15; 11 (14) :5233-40. PubMed PMID:16033841. Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2005 Jul 19; 102 (29) :10238-43. PubMed PMID:16006513; PubMed Central PMCID: PMC1174923. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005 Aug; 7 (3) :413-21. PubMed PMID:16049314; PubMed Central PMCID: PMC1867544. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005 Aug 9; 102 (32) :11355-60. PubMed PMID:16051706; PubMed Central PMCID: PMC1183537. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11 (18) :6650-6. PubMed PMID:16166444. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20; 102 (51) :184438. PubMed PMID:16339315; PubMed Central PMCID: PMC1317954. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006 Jan; 19 (1) :59-68. PubMed PMID:16118624. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL, Ewen ME. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet. 2006 Jan; 38 (1) :118-23. PubMed PMID:16369533. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 1; 12 (1) :152-8. PubMed PMID:16397037. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate. 2006 Feb 1; 66 (2) :135-45. PubMed PMID:16161153. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res. 2006 Feb; 4 (2) :79-92. PubMed PMID:16513839. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006 Feb 17; 21 (4) :509-19. PubMed PMID:16483932. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006 May; 8 (2) :209-17. PubMed PMID:16645207; PubMed Central PMCID: PMC1867588. Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A, Ientile R, Violi MA, Loda M, Trimarchi F, Vermiglio F. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab. 2006 Jun; 91 (6) :2021-6. PubMed PMID:16595601. 40 Loda - CV 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 1; 66 (11) :5723-8. PubMed PMID:16740710. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia. 2006 Jun; 8 (6) :458-64. PubMed PMID:16820091; PubMed Central PMCID: PMC1601473. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun; 5 (1) :61-6. PubMed PMID:16859581. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006 Jul; 55 (7) :1000-6. PubMed PMID:16407376; PubMed Central PMCID: PMC1856352. Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos AP, Fletcher JA, Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol. 2006 Jul; 209 (3) :369-75. PubMed PMID:16583360. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol. 2006 Aug; 19 (8) :1083-90. PubMed PMID:16699497. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006 Aug 1; 66 (15) :7668-77. PubMed PMID:16885368. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006 Sep; 30 (9) :1175-83. PubMed PMID:16931963. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006 Sep 1; 66 (17) :8625-32. PMID:16951176. Tholouli E, Hoyland JA, Di Vizio D, O'Connell F, Macdermott SA, Twomey D, Levenson R, Yin JA, Golub TR, Loda M, Byers R. Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. Biochem Biophys Res Commun. 2006 Sep 22; 348 (2) :628-36. PubMed PMID:16893519. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006 Oct; 210 (2) :147-54. PubMed PMID:16850502. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006 Oct; 30 (10) :1281-91. PubMed PMID:17001160. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006 Nov; 8 (5) :582-8. PubMed PMID:17065427; PubMed Central PMCID: PMC1876166. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol. 2007 Jan; 20 (1) :15-22. PubMed PMID:17086168. Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossage K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 2007 Feb; 9 (1) :20-9. PMCID: PMC2248801. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39 (3) :347-51. PubMed PMID:17293865. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007 Mar 15; 13 (6) :1685-94. PubMed PMID:17363521. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island 41 Loda - CV 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. methylator phenotype. Hum Pathol. 2007 Apr; 38 (4) :585-92. PubMed PMID:17239930; PubMed Central PMCID: PMC2000822. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007 Apr; 38 (4) :614-20. PubMed PMID:17270239. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450 (5) :529-37. PubMed PMID:17372756. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007 Jun; 38 (6) :842-9. PubMed PMID:17350669. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007 Jun; 11 (6) :555-69. PubMed PMID:17560336. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007 Jul; 9 (3) :305-14. PubMed PMID:17591929; PubMed Central PMCID: PMC1899428. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther. 2007 Aug; 6 (8) :1263-8. PubMed PMID:17786030. Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007 Sep; 9 (4) :441-51. PubMed PMID:17690213; PubMed Central PMCID: PMC1975106. Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A. 2007 Nov 6; 104 (45) :17771-6. PubMed PMID:17978178; PubMed Central PMCID: PMC2077015. Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL. Evaluation of whole genome amplification protocols for array and oligonucleotide CGH. Diagn Mol Pathol. 2007 Dec; 16 (4) :198-206. PubMed PMID:18043282. Febbo PG, Mulligan MG, Slonina DA, Stegmaier K, Di Vizio D, Martinez PR, Loda M, Taylor SC. Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis. BMC Genomics. 2007 Dec 18; 8:461. PubMed PMID:18088408; PubMed Central PMCID: PMC2244637. Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding Z, Jiang S, Guney I, Kang GH, Shin E, Hahn WC, Loda MF, Abate-Shen C, Weissleder R, Chin L. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008; 3 (12) :e3949. PubMed PMID:19079609; PubMed Central PMCID: PMC2597248. Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2008 Feb; 21 (2) :150-8. PubMed PMID:18084250. Silva Neto B, Smith GL, Mandeville JA, Vanni AJ, Wotkowicz C, Rieger-Christ KM, Baumgart E, Jacobs MA, Cohen MS, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Prognostic significance of altered p120 ctn expression in bladder cancer. BJU Int. 2008 Mar; 101 (6) :746-52. PubMed PMID:17922855. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE. Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol. 2008 Mar; 39 (3) :410-9. PubMed PMID:18261625. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008 Mar; 15 (1) :191-205. PubMed PMID:18310287. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008 Apr 28; 7:35. PubMed PMID:18442408; PubMed Central PMCID: PMC2383925. Benedettini E, Nguyen P, Loda M. The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf). 2008 May; 14 (5) :195-201. PubMed PMID:20953243; PubMed Central PMCID: PMC2955448. Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008 Jun; 21 (6) :676-84. PubMed PMID:18327211. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer M.D., Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008 Jun 1; 14 (11) :3380-5. PubMed PMID:18519767. 42 Loda - CV 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MP, Freeman MR. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle. 2008 Jul 15; 7 (14) :2257-67. PubMed PMID:18635971. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 7; 454 (7205) :776-9. PubMed PMID:18594509; PubMed Central PMCID: PMC2750091. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14 (2) :146-55. PubMed PMID:18691549; PubMed Central PMCID: PMC2583442. Ince TA, Ward JM, Valli VE, Sgroi D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD. Do-it-yourself (DIY) pathology. Nat Biotechnol. 2008 Sep; 26 (9) :978-9; discussion 979. PubMed PMID:18779800. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455 (7212) :547-51. PubMed PMID:18794900; PubMed Central PMCID: PMC2587138. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008 Oct 15; 113 (8) :2129-38. PubMed PMID:18720359; PubMed Central PMCID: PMC2597625. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, Rangel AL, Veiga SS, Raposo HF, Oliveira HC, Loda M, Coletta RD, Graner E. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer. 2008 Dec 1; 123 (11) :2557-65. PubMed PMID:18770866. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR. Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma. J Cell Mol Med. 2008 Nov 14. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88 (12) :1340-8. PubMed PMID:18838960. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Pcadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int. 2008 Dec; 102 (11) :1707-14. PubMed PMID:18990147. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26 (35) :5713-20. PubMed PMID:18955444; PubMed Central PMCID: PMC2630484. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58 (1) :90-6. PubMed PMID:18832519; PubMed Central PMCID: PMC2679586. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009 Jan; 27 (1) :77-83. PubMed PMID:19098899; PubMed Central PMCID: PMC3057643. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009 Jan 27; 2 (55) :ra2. PubMed PMID:19176516; PubMed Central PMCID: PMC2906144. Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15 (6) :2116-22. PubMed PMID:19276255; PubMed Central PMCID: PMC3059545. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 1; 101 (7) :519-32. PubMed PMID:19318631; PubMed Central PMCID: PMC2664091. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009 May; 119 (5) :1093-108. PubMed PMID:19363294; PubMed Central PMCID: PMC2673846. 43 Loda - CV 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009 May 1; 15 (9) :3023-8. PubMed PMID:19366827. Flavin RJ, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009 May; 19 (4) :641-7. PubMed PMID:19509563. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2009 May 16; PubMed PMID:19450994. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009 Jun 1; 15 (11) :3680-9. PubMed PMID:19470727. Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S. p63 promotes cell survival through fatty acid synthase. PLoS One. 2009 Jun 11; 4 (6) :e5877. PubMed PMID:19517019; PubMed Central PMCID: PMC2691576. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009 Jul; 218 (3) :292-300. PubMed PMID:19449367. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol. 2009 Jul 20; 27 (21) :3459-64. PubMed PMID:19433685; PubMed Central PMCID: PMC2717753. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer. Cell. 2009 Jul 23; 138 (2) :245-56. PubMed PMID:19632176; PubMed Central PMCID: PMC2726827. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13 (8B) :1977-86. PubMed PMID:19040416 Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009 Aug; 89 (8) :857-66. PubMed PMID:19488035. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009 Aug; 36 (4) :290-301. PubMed PMID:19664490. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal. 2009 Aug 18; 2 (84) :ra44. PubMed PMID:19690330; PubMed Central PMCID: PMC2928478. Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S. Systemslevel modeling of cancer-fibroblast interaction. PLoS One. 2009 Sep 3; 4 (9) :e6888. PubMed PMID:19727395; PubMed Central PMCID: PMC2731225. Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15 (18) :5931-6. PubMed PMID:19723652; PubMed Central PMCID: PMC2745516. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 1; 69 (19) :7803-10. PubMed PMID:19773438; PubMed Central PMCID: PMC2756305. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009 Nov 1; 69 (21) :8341-8. PubMed PMID:19826035; PubMed Central PMCID: PMC2783286. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape 44 Loda - CV 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463 (7283) :899-905. PubMed PMID:20164920; PubMed Central PMCID: PMC2826709. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A. 2010 Feb 23; 107 (8) :3698-703. PubMed PMID:20133671; PubMed Central PMCID: PMC2840447. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16 (3) :286-94. PubMed PMID:20154697; PubMed Central PMCID: PMC2903662. Priolo C, Agostini M, Vena N, Ligon AH, Fiorentino M, Shin E, Farsetti A, Pontecorvi A, Sicinska E, Loda M. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol. 2010 Apr; 176 (4) :1901-13. PubMed PMID:20167861; PubMed Central PMCID: PMC2843479. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010 Apr 13; 3 (117) :ra29. PubMed PMID:20388916; PubMed Central PMCID: PMC2982149. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70 (8) :3136-9. PubMed PMID:20388772; PubMed Central PMCID: PMC3049266. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010 May 4; 107 (18) :8352-6. PubMed PMID:20404174. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010 May 11; 102 (10) :1495-502. PubMed PMID:20461092; PubMed Central PMCID: PMC2869174. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A. 2010 Jun 15; 107 (24) :11002-7. PubMed PMID:20534477; PubMed Central PMCID: PMC2890726. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010 Jul; 177 (1) :415-23. PubMed PMID:20489150; PubMed Central PMCID: PMC2893683. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010 Aug; 19 (8) :2088-96. PubMed PMID:20647401; PubMed Central PMCID: PMC2923431. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31 (9) :1597-603. PubMed PMID:20576793; PubMed Central PMCID: PMC2930803. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 1; 28 (25) :3958-64. PubMed PMID:20679621. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103 (7) :1025-33. PubMed PMID:20808308; PubMed Central PMCID: PMC2965861. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2010 Nov 8; PubMed PMID:21061350. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6 (11) :e1001204. PubMed PMID:21085629; PubMed Central PMCID: PMC2978684. Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 2011 Feb; 107 (4) :656-63. PubMed PMID:20735391. 45 Loda - CV 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470 (7333) :269-73. PubMed PMID:21289624. Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O. RET protein expression in papillary renal cell carcinoma. Urol Oncol. 2011 Mar 9; PubMed PMID:21396847. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011 Mar 15; 117 (6) :1172-82. PubMed PMID:21381010. Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM. Transgenic expression of polyoma virus middle T antigen in the mouse prostate gives rise to carcinoma. J Virol. 2011; 85(11):5581-92. PMID:21411524. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011 Mar 24; 471 (7339) :513-7. PubMed PMID:21430779. Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP. Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. Cancer Res. 2011 2011 May 15;71(10):3669-75 PMID:21444676. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2011 May-Jun;29(3):302-8. Epub 2009 May 17. PubMed PMID: 19450994. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors. Am J Surg Pathol. 2011 May 5. [Epub ahead of print] PubMed PMID: 21552115. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. J Clin Oncol. 2011 May 2. [Epub ahead of print] PubMed PMID: 21537050. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E. Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression. J Clin Oncol. 2011 May 2. [Epub ahead of print] PubMed PMID: 21537045. Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF. β-Catenin Is a Useful Adjunct Immunohistochemical Marker for the Diagnosis of Pulmonary Lymphangioleiomyomatosis. Am J Clin Pathol. 2011 May;135(5):776-82. PubMed PMID: 21502434. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors. Am J Surg Pathol. 2011 Jun;35(6):81626. PubMed PMID: 21552115. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27. PubMed PMID: 21960694 Berman DM, Bosenber M, Orwant RL, Thurberg BL, Draetta G, Fletcher CDM, Loda M. Investigative pathology: leading the post-genomic revolution. Laboratory Investigation. 2012 Jan; 92(1):4-8. PubMed PMID: 21986811. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, Loda M. CMyc is activated via USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discovery. 2012 2(3): 236-47. PubMed PMID: 22585994. Editorial in the same issue: Nelson WG, De Marzo AM, Yegnasubramanian S. USP2a activation of MYC in prostate cancer. Cancer Discov. 2012 Mar;2(3):206-7. Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis. 2012 Feb; 33(2): 404-412. PubMed PMID: 22159221. Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M, Hodi FS. C-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32. PubMed PMID: 22343486. Kim J, Kim WJ, Liu Z, Loda MF, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012 Mar 15; 11(6): 1123-30. PubMed PMID: 22370483. Fiore C, Bailey D, Conlon N, Wu X, Martin N, Fiorentino M, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R. Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. J Clin Pathol. 2012 Jun; 65(6): 496-502. PubMed PMID: 22447914. 46 Loda - CV 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR, Pyne S, Agostini M, Freeman MR, Loda M. The Ubiquitin Specific Protease USP2a Prevents Endocytosis-Mediated EGFR Degradation. Oncogene. 2012 Jun; PubMed PMID: 22710717. Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7. PubMed PMID: 22730461. Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS One. 2012; 7(6):e38881. Epub 2012 Jun 15. PubMed PMID: 22719973. PMCID: 3376148 Pettersson A Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2: ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep. 21(9):1497-509. PMID: 22736790. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XL, Brown M. EZH2 Oncogenic Activity in Castration Resistant Prostate Cancer is Polycomb-Independent. Science 2012 Dec 14;338(6113):1465-9 Kim J, Keay SK, You S, Loda M, Freeman MR. A synthetic Form of Frizzled 8-Associated Antiproliferative Factor Enhances p53 Stability through USP2a and MDM2. PLoS One. 2012;7(12):e50392. PMID: 23236372. PMCID: PMC3516501. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan;3(1):44-51. PMID: 23258246. PMCID: PMC3546223. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013:823849. Epub 2013 Jan 20. PMID: 23401687 Habibollahi, P., van den Berg, N. S., Kuruppu, D., Loda, M., and Mahmood, U. (2013) Metformin-an Adjunct Antineoplastic Therapy--Divergently Modulates Tumor Metabolism and Proliferation, Interfering with Early Response Prediction by 18F-FDG PET Imaging. J Nucl Med 2013 Feb;54(2):252-8. PMID: 23376854. PMCID: 3703242. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013 Mar 15;27(6):683-98. PMID: 23512661 Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induced androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar 1;123(3):1109-22. Epub 2013 Feb 15. PMID: 23426182. Chavarro JE, Kenfield SA, Stampfer MJ, Loda M, Campos H, Sesso HD, Ma J. Blood Levels of Saturated and Monounsaturated Fatty Acids as Markers of De Novo Lipogenesis and Risk of Prostate Cancer. Am J Epidemiol. 2013 Aug 28. [Epub ahead of print] Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 1;73(9):2718-36. doi: 10.1158/0008-5472.CAN-12-4213. Epub 2013 Apr 22. PMID: 23610450. PMCID: PMC3644021. Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, Ma J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May: 73(7):700-5. PMID: 23129481. PMCID: 3640488. Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M. Gleason Grade Progression Is Uncommon. Cancer Res. 2013 Aug 15;73(16):5163-5168. PMID: 23946472 [PubMed - indexed for MEDLINE] PMCID: PMC3775342 Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn SP, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci EL Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Aug 27. PMID: 23983239 [PubMed - indexed for MEDLINE]. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2. PMCID: 23727860. 47 Loda - CV 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. Benassi B, Marani M, Loda M, Blandino G. USP2a alters chemotherapeutic response by modulating redox. Cell Death Dis. 2013 Sep 26;4:e812. doi: 10.1038/cddis.2013.289. PMID: 24071644. PMCID: 3789164. Kaelin W, Livingston D, Loda M, Vousden K, Mihich E. Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. Cancer Res. 2013 Oct 15;73(20):6124-7. doi: 10.1158/0008-5472.CAN-13-2445. Epub 2013 Oct 4. PMID: 24097824. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90. doi: 10.1093/jnci/djt332. Epub 2013 Nov 30. PMID: 24292212. PMCID: PMC3866157 [Available on 2014/12/18]. Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63. doi: 10.1158/1055-9965.EPI-13-0668. Epub 2013 Oct 15. PMID: 24130224. PMCID: PMC3893763 [Available on 2014/12/1]. Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. Cell Cycle. 2014 Jan 13;13(5). PMID: 24418822. PMCID: PMC3979921. Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb;106(2):djt430. doi: 10.1093/jnci/djt430. Epub 2014 Jan 24. PMID: 24463248. PMCID: PMC3952200. Selvarajah S, Pyne S, Chen E, Sompallae R, Ligon AH, Nielsen GP, Dranoff G, Stack E, Loda M, Flavin R. HighResolution Array CGH and Gene Expression Profiling of Alveolar Soft Part Sarcoma. Clin Cancer Res. 2014 Mar 15;20(6):1521-30. doi: 10.1158/1078-0432.CCR-13-2090. Epub 2014 Feb 3. PMID: 24493828. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis EMBO Mol Med 2014 Apr;6(4):519-38. Accompanying Closeup editorial in the same issue: AMPed up to treat in prostate cancer: Novel AMPK activators emerge for cancer therapy. Schiewer MJ, Knudsen KE. EMBO Mol Med. 2014 Feb 4. PMID: 24497570. Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE. Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clin Cancer Res. 2014 Mar 13. PMID: 24486590. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13. PMID: 24625776. PMCID: PMC4122326. Flavin RJ, Pettersson A, Hendrickson WK, Fiorentino M, Finn SP, Kunz L, Judson G, Lis RT, Bailey D, Fiore C, Nuttall EJ, Martin NE, Stack EC, Penney KL, Rider JR, Sinnott JA, Sweeney CS, Sesso HD, Fall K, Giovannucci EL, Kantoff PW, Stampfer MJ, Loda M, Mucci LA. SPINK1 Protein Expression and Prostate Cancer Progression. Clin Cancer Res. 2014 Mar 31. [Epub ahead of print]. PMID: 24687926. [PubMed - as supplied by publisher]. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May;32(5):479-84. doi: 10.1038/nbt.2892. Epub 2014 Apr 20. PMID: 24752078. PMCID: PMC4034575. Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 May 21. doi: 10.1002/cam4.262. [Epub ahead of print]. PMID: 24846059. Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 May 22. doi: 10.1002/path.4379. [Epub ahead of print]. PMID: 24852265. González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition. Cancer Discov. 2014 May 27. [Epub ahead of print]. PMID: 24866151. 48 Loda - CV 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF. 5αReductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA. 2014 June 2. [Epub ahead of print]. PMID: 24887392. Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, Mucci LA. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Jun 12. [Epub ahead of print] PMID: 24925673. Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer 2014 July 17. [Epub ahead of print]. PMID: 25032733. Taplin ME, Montgomery B, Logothetics CJ, Bubley GJ, Richie JP, Dalkin BL, Sandra MG, Davis JW, Loda M, True LD, Tronosco P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Hagg CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. J Clin Oncol. 2014 Oct 13 [Epub ahead of print] PMID: 25311217. Chen E, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RT, Kantoff P, Montgomery B, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Resceptors. Clin Cancer Res. 2014 Oct 15. [Epub ahead of print] PMID: 25320358. Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, Schultz D, Scaglia N, McDunn JE, SeMarzo A, Loda M. AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer. Cancer Res. 2014 Dec 15;74(24):7198-204. PMID: 25322691. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2014 Oct 22. [Epub ahead of print] PMID: 25450031. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Desphande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes CH, Engelman JA, Bardessy N. Combined MED and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Research. 2014 Oct 27. [Epub ahead of print] PMID: 25348516. Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ. Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue. Cancer Epidemiol Biomarkers Prev. 2014 Nov 4. [Epub ahead of print] PMID: 25371445. Dadras SS, Lin RJ, Razavi G, Kawakami A, Du J, Feige E, Milner DA, Loda M, Granter SR, Detmar M, Widlund HR, Horstmann MA, Fisher DE. A Novel Role for Microphthalmia-Associated Transcription Factor-Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. Am J Pathol. 2014 Nov 6. [Epub ahead of print] PMID: 25447045. Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Jewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda M, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Nov. Epub 2014 Aug 21. PMID: 25143071. Crawley DJ, Holmberg L, Melvin JC, Loda M, Chowdhury S, Rudman SM, Van Hemelrijck M. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014 Dec 19;14(1):985. [Epub ahead of print] PMID: 25526881 Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015 Jan 15;21(2):396-404. doi: 10.1158/1078-0432.CCR-14-1591. Epub 2014 Oct 27. PMID: 25348516. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Feb 26. [Epub ahead of print] PMID: 25720673 Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 9. PMCID: PMC4392457. Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O. Molecular Differences in Transition Zone and Peripheral Zone Prostate Tumors. Carcinogenesis. 2015 Apr 13. pii: bgv051. [Epub ahead of print] PMID: 25870172. 49 Loda - CV 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. Brown M, Chinnaiyan A, Farsetti A, Livingston DM, Loda M, Schuele R, Mihich E. 26th pezcoller symposium: cancers driven by hormones. Cancer Res. 2015 Apr 1;75(7):1177-80. doi: 10.1158/0008-5472.CAN-14-2902. Epub 2015 Mar 18. PMID: 25788695. Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD. Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer. Cancer Res. 2015 Mar 15;75(6):1021-34. doi: 10.1158/0008-5472.CAN-14-1596. PMID: 25770260. Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clin Cancer Res. 2015 Mar 2. [Epub ahead of print] PMID: 25733599. Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA; on behalf of the Transdisciplinary Prostate Cancer Partnership ToPCaP. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Mar 1. doi: 10.1002/pros.22973. [Epub ahead of print] PMID: 25728532. Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S, Sundaram M, Majumder PK. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015 Feb 27;6:6169. doi: 10.1038/ncomms7169. PMCID: PMC4351621. Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun;36(6):639-47. doi: 10.1093/carcin/bgv048. Epub 2015 Apr 11. PMID: 25863129. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Feb 26. doi: 10.1002/cam4.432. [Epub ahead of print] PMID: 25720673. Kehr E, Masry P, Lis R, Loda M, Taplin ME, Hirsch MS. Detecting Metastatic Prostate Carcinoma in Pelvic Lymph Nodes Following Neoadjuvant Hormone Therapy: The Eyes Have It! Histopathology. 2015 May 27. PMID: 26018610 [Epub ahead of print] Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21. PMID: 26000489 [PubMed – in process]. Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M. Comparing Platforms for Messenger RNA Expression Profiling of Archival FormalinFixed, Parrafin-Embedded Tissues. J Mol Diagn. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002. Epub 2015 Apr 30. PMID: 25937617. Martin NE, Gerke T, Sinnott JA, Stack EC, Andren O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Jun 29. pii: molcanres.0569.2014. [Epub ahead of print] PMID: 26124442. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Jul 20. doi: 10.1038/ng.3343. [Epub ahead of print] PMID: 26192918. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne J, Lewis JS, Reuter V, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. A Phase I/II Study for Analytic Validation of 89ZrJ591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015 Jul 14. pii: clincanres.0552.2015. [Epub ahead of print] PMID: 26175541. Invited Reviews, Chapters, Editorials: 50 Loda - CV 1. Loda M. PCR-based methods for the detection of mutations in oncogenes and tumor suppressor genes. (Molecular Diagnostics symposium) Hum Pathol; 25:564-71, 1994. 2. Magi-Galluzzi C, Loda M. Molecular pathology of preinvasive neoplasia in the prostate gland. Eur Urol; 30:167-76, 1996. PMID: 8875197. 3. Del Sal G, Loda M, Pagano M. Cell cycle and cancer: critical events at the G1 restriction point. Critical Reviews in Oncogenesis; 7(1&2):127-42, 1996. PMID: 9109501. 4. Loda M, DeLellis RA. Molecular diagnostic techniques. In: Silverberg SG, DeLellis RA, Frable WJ, eds. Principle and Practice of Surgical and Cytopathology. New York: Churchill Livingstone; pp 77-94, 1997. 5. Ellis FH Jr, Loda M. Role of surveillance endoscopy, biopsy, and sub-cellular markers in early detection of Barrett’s carcinoma. Diseases of the esophagus; 10:165-71, 1997. 6. Loda M. Molecular Biology of Gastrointestinal Disorders. In: Ming SC, Goldman H, eds. Pathology of Gastrointestinal Tract, 2nd ed. Williams & Wilkins; pp 133-53, 1998. 7. Jessup JM, Loda M. Prognostic markers in rectal carcinoma. Seminars in Surg Oncol; 15(2):131-40, 1998. PMID: 9730420 8. Jessup JM, Loda M, Bleday R. Clinical and molecular prognostic factors in sphincter preserving surgery for rectal cancer. Sem Rad Oncol; 8:54-9, 1998. PMID: 9516585 9. Magi-Galluzzi C, Murphy M, Cangi GM, Loda M. Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Analyt Quant Cytol Histol; 20:343-350. 1998. 10. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev; 7(4):337-44, 1998-99. 11. Loda M. p27KIP1: androgen regulation and prognostic significance in prostate cancer. Autumnal IAP Meeting Sassari Seminars of Histopathology. Adv Clin Path; 4(4):226-32, 2000. 12. Signoretti S, and Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol;159(1):13-6, 2001. PMID:11438447; PMCID: PMC1850394 13. McMenamin ME, Loda M. Molecular diagnostic studies in pulmonary diseases. In: Shields TW, LoCicero J III, Ponn RB, eds. General Thoracic Surgery, 5th ed.; pp 243-257, 2000. 14. Thomas GVH, Loda M. Molecular staging of prostate cancer. In: Kantoff P, D’Amico, Carrol P, eds. Prostate Cancer. Lippincott, Williams & Wilkins; pp 287-303, 2002. 15. Sellers WR and Loda M. The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer? Cancer Cell; 2(5):349-50, 2002. PMID: 12450788 16. Rossi S, Loda M. The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes. Breast Cancer Res. 2003; 5 (1):16-22. PMID:12559040 17. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem; 91(1):47-53, 2004. 18. Ellis F.H.Jr, and Loda M. p27 and Barrett’s Esophagus: a review. Diseases of the Esophagus ; 17(2):113-7, 2004. 19. McMenamin ME, Loda M. Molecular diagnostic studies in pulmonary diseases. In: Shields TW, LoCicero J III, Ponn RB, eds. General Thoracic Surgery, 6th ed.; pp 261-283, 2005. 20. Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle; 5(2): 138-41, 2006. PMID: 16357539 51 Loda - CV 21. Signoretti S, Loda M. Prostate stem cells: from development to cancer. Sem Cancer Biol;17(3):219-24, 2007 22. Rubin M, Loda M. Prostate cancer: molecular pathology and biologic determinants. In: Vogelzang NJ, Scardino PT, Shipley WU. Debruyne FMJ, Linehan M, eds. Comprehensive Textbook of Genitourinary Oncology, 3rd ed, Lippincott Williams & Wilkins, Chapter 6B pp 60-77, c2006 . 23. Rubin MA, Chinnaiyan AM, Loda M. New concepts in the molecular pathology of prostate cancer. In: Kirby: Prostate Cancer – Practice & Principles, Taylor & Francis, c2006. 24. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007 39(9):1562-8. 25. Loda M, P. Nguyen, Benedettini E. The pathogenesis of prostate cancer: from molecular to metabolic alterations. Mini-symposium, “Diagnostic Molecular Pathology” Guest Editor Richard Byers, Diagnostic Histopathology 14:5, 2008 26. Priolo C, Oldridge D, Renatus M, Loda M. Targeting De-Ubiquitinating Enzymes Book Chapter in: “Modulation of Protein Stability in Cancer Therapy” edited by Kathleen Sakamoto and Dr. Eric Rubin. Springer US (submitted 2/08). 27. Levenson R, Fornari A, Loda M. Multispectral Imaging and Pathology: Seeing More Expert Opinion in Medical Diagnostics (accepted, 8/08). 28. Loda, M, Sicinska E. Sarcoma: Diagnosis and Management (part of the M.D. Anderson Solid Tumor Oncology Series) contributing to chapter on Mouse Models for the “Developmental Therapeutics in Medical Management” Section (in press). 29. Loda M. Invited commentary in “community corner”, Nature Medicine. Commentary on Leong, K.G., Wang, B.-E., Johnson, L. & Gao, W.Q. Generation of a prostate from a single adult stem cell. Nature published online, (22 October 2008). 30. Loda M. Invited commentary in “community corner”, Nature Medicine. Commentary on Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science published online, (9 April 2009). 31. Priolo C, Oldridge G, Loda M. Modulation of Protein Stability in Cancer Therapy. Springer. 2009; (8)121-146. DOI 10.1007/978-0-387-69147-3. 32. Priolo C, Oh WK, Loda M. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. iDrugs. 2009 Mar;12(3):165-8. 33. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P.Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009 Aug; 36(4):290-301. Review.PMID: 19664490 34. Zadra G, Priolo C, Patnaik A, Loda M. New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK. Clin Cancer Res. 2010 Apr 27. PMID: 20423984 35. Loda M, Kaelin WG Jr. Prostate cancer: beta control your hormones. Cancer Cell. 2010 Apr 13;17(4):311-2. PMID: 20385354 36. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am. 2010 Feb;37(1):131-41 PubMed PMID:20152526. 37. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr;6(4):551-62.PMID: 20373869 38. Martin N, Loda M. Prostate Cancer: Molecular Pathology and Biologic Determinants. Comprehensive Textbook of Genitoruninary Oncology, 4th ed, Lippincott Williams & Wilkins, Chapter 4B pp 39-50, 2011. 52 Loda - CV 39. Benedettini E, Penney K, Fiorentino M, Loda M. Tumor Biology. Recent Advances in Prostate Cancer-Basic Science Discoveries and Clinical Advances, Editors Donald J. Tindall and Peter T. Scardino, World Scientific Publishing Company, Chapter 6 pp 133-158, July 2011. 40. Martin NE, Mucci LA, Loda M, DePinho RA. “Prognostic determinants in prostate cancer” Cancer J. 2011 NovDec;17(6):429-37. PMID: 22157287. Issue devoted to Frontiers of Personalized Cancer Medicine. Editors Drs. DeVita, Lawrence, and Rosenberg. 41. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011 Jan; 223 (2): 283-94. PubMed PMID: 21125681. 42. Zadra G, Photopoulos C, Loda M. The fat side of Prostate Cancer. Issue devoted to: Molecular and Cell Biology of Lipids. Biochim Biophys Acta. 2013 Oct;1831(10):1518-32. PMID: 23562839 43. Labbé DP, Zadra G, Ebot EM, Mucci LA, Kantoff PW, Loda M, Brown M. Role of diet in prostate cancer: the epigenetic link. Oncogene. 2014 Dec 22. doi: 10.1038/onc.2014.422. 44. Zadra G, Batista JL, Loda M. Dissecting the dual role of AMPK in cancer: from experimental to human studies. Mol Cancer Res. 2015 Jul;13(7):1059-72. doi: 10.1158/1541-7786.MCR-15-0068. Epub 2015 May 8. Review. PMID: 25956158. 45. Cacciatore S, Loda M. Innovation in Metabolomics to Improve Personalized Healthcare. Annals of the NY Acad Sci. 2015 Jun;1346(1):57-62. doi: 10.1111/nyas.12775. Epub 2015 May 26. PMID: 26014591. 46. Brown M, Chinnaiyan A, Farsetti A, Livingston DM, Loda M, Schuele R, Mihich E. 26th Pezcoller symposium: cancers driven by hormones. Cancer Res. 2015 Apr 1; 75(7):1177-80. doi: 10.1158/0008-5472.CAN-14-2902. Epub 2015 Mar 18. PMID: 25788695. Theses 1. M.D. Thesis Loda M. Prognostic significance of amino acid variations in cirrhotic patients with bleeding complications. Milan, Italy: Univ. of Milan: 1980. 2. Emergency Surgery Residency Thesis Loda, M. Prognostic significance of amino acid hepatic clearance in cirrhotic patients. Milan, Italy: Univ of Milan: 1985. Narrative Report My approach to research originates from unresolved pathogenetic mechanisms of disease and extends to explore at the “clinical” level an unproven assumption. My research is currently entirely focused on prostate cancer. Below I summarize some examples of basic, translation and clinical research I have pursued over the years. The cyclin dependent kinase inhibitor p27, its role as a biomarker and its regulation I have been interested in the disruption of cell cycle regulation in human solid tumors. In particular, my attention has focused on the cell cycle inhibitor p27. We were the first to establish the prognostic role of p27 in colon tumors (Loda et al, Nature Med 1997). In addition, utilizing degradation assays in human colon tumor cell lysates, a tumor-specific proteolytic mechanism targeting p27 was discovered in this paper. The lack of correlation between p27 expression and proliferative rate in colon cancer pointed to a role other than inhibition of proliferation (e.g. invasive or metastatic potential) by this protein in human tumors. In order to test the hypothesis that loss of p27 was associated with the development of metastases, we compared primary and 53 Loda - CV metachronous liver metastases in patients with colon cancers and discovered that p27 protein (but not mRNA) was lost in tumors from the same patients as these became metastatic years after the primary (Thomas et al, Am J Pathol, 1998). These findings strongly suggest that p27 protein is associated with the development of metastases. Further, these data suggest that tumors gain metastatic potential by eliminating p27 with the same degradation mechanism first shown by us in primary colon carcinomas. We also confirmed p27’s role as an independent prognostic marker in Stage 1 breast cancers (Tan et al Cancer Res., 1997), in organ confined prostate carcinomas (Yang et al J Urol, 1998) and esophageal carcinomas (Singh et al, Cancer Res, 1998). In this tumor type the mechanism of p27 inactivation was nuclear exclusion. Furthermore, we established a surgical murine model of Barrett’s Associated Adenocarcinoma in a p27 knock-out background (Ellis et al, J Thor Cardiov Surg - 2001). Because of the role of p27 in the inhibition of Cdk2, we tested the hypothesis that Flavopiridol, an inhibitor of cyclin dependent kinases, may prevent tumor formation in this animal model and demonstrated that this was indeed the case (Lechpammer et al. Oncogene, 2005). In a castration-regeneration rat prostate model, we elucidated the regulation of p27 in vivo and its relationship to androgens (Waltregny et al Mol Endocrinol 2001). The S-phase kinase-associated protein Skp2 is required for the ubiquitin-mediated degradation of p27. We determined that higher levels of Skp2 are present more frequently in ER negative breast tumors than in ER positive cases. Interestingly, the subset of ER negative breast carcinomas overexpressing Skp2 are also characterized by high tumor grade, negativity for Her-2, basal-like phenotype (i.e. “triple negative” tumors), high expression of certain cell cycle regulatory genes and low levels of p27 protein. We also found that Skp2 induces a decrease of adhesion-independent growth in breast cancer cells, and suggested that deregulated Skp2 expression might play a role in the development of resistance to antiestrogens (Signoretti et al J Clin Invest 2002). Recently, we demonstrated that Skp2 Overexpression is an independent marker of recurrence-free survival following radical prostatectomy (Nguyen et al Urol Oncol. 2009). More recently, a role for p27 in preventing invasion of the PIN phenotype obtained in probasin-myristilated-Akt mice was published in Cancer Cell (Majumder et al, 2008). In addition, the predictive role of p27 in colon cancer was substantiated in a large CALGB cohort of colon cancer patients (Bertagnolli et al, Clin Cancer Res, 2009). The de-ubiquitinating enzyme USP2a as an oncogene The ubiquitin system regulates the degradation of key intracellular proteins including p27. The selective degradation of a given protein through ubiquitination involves the activation of a signaling cascade that results in the covalent attachment of a poly-ubiquitin chain to protein target. The formation of a poly-ubiquitin chain, acts as a signal for degradation by the proteasome. The enzymatic cascade responsible for ubiquitin conjugation can be reversed by de-ubiquitinating enzymes or isopeptidases. With the help of funding from my RO1 aimed at the identification of de-ubiquitinating enzymes and their targets, we discovered a novel de-ubiquitinating enzyme, which we named USP2a. We have extensively studied this androgen responsive isopeptidase and discovered that it binds to and stabilizes fatty acid synthase (FASN), preventing its degradation (Graner et al Cancer Cell, 2004). We demonstrated that USP2a behaves as an oncogene in prostate cancer (Priolo et al, Cancer Res. 2006). Thus, therapeutic targeting this isopeptidase and its substrates (which also include Mdm2 and Cyclin D1), are novel and potentially important therapeutic strategies initiated by our group. Our group recently highlighted a new mechanism by which USP2a enhances c-Myc levels via the modulation of specific subsets of microRNAs in prostate cancer. We also identified a distinct mRNA signature, which is enriched for c-Myc-regulated transcripts and transcription factor binding sites in USP2a over-expressing prostate cancer cells. We demonstrated that these genes are associated with an invasive phenotype in human prostate cancer, and that the proliferative and invasive properties of USP2a over-expressing cells are c-Myc-dependent. These results highlight an unrecognized mechanism of c-Myc regulation in prostate cancer and suggest alternative therapeutic strategies in targeting Myc (Benassi et al, Cancer Discovery, 2012). We had previously determined that USP2a interacted with clathrin heavy chain in prostate cancer cell lysates in an affinity chromatography experiment (Graner et al Cancer Cell, 2004). Clathrin is a structural protein required for internalization of RTKs and for their transport on early endosomes. This interaction suggested that USP2a could be involved in endocytosis. We indeed discovered that USP2a localizes to early endosomes stabilizing EGFR, the receptor, amplifying downstream signaling activity from the receptor. Since our data indicate that USP2a antagonizes EGFR endocytosis, regulation of deubiquitination could potentially be exploited therapeutically in cancers over-expressing this tyrosine kinase receptor (Liu et al, Oncogene. 2012). Metabolism and prostate cancer Metabolomics is the quantitative measurement of the metabolic response to external stimuli or genetic alterations and can detect and quantify low-molecular weight metabolites produced by living cells. The metabolites of living cells are seen as the end products of the biological hierarchy starting with activated genes (genome) and extending over the collection of gene transcripts (transcriptome) and proteins (proteome). Uncontrolled proliferation does not occur in normal cells because these do not normally take up nutrients from their environment unless stimulated to do so by growth factors. Cancer cells overcome this growth factor dependence by acquiring genetic mutations that result in altered metabolic pathways that stimulate cell growth by either providing fuel for energy or by efficiently incorporating nutrients into biomass. Thus, metabolic alterations can occur as a consequence of genetic events (e.g. Akt activation results in increased glycolysis). Alternatively, metabolic alterations are primary events in 54 Loda - CV cancer but require genetic alterations in critical pathways for oncogenesis to occur (e.g. succinate dehydrogenase, fumarate hydratase, isocitrate dehydrogenase mutations, PKM2 etc). Either way, our hypothesis is that genetic alterations and altered metabolic pathways go hand in hand in a tumor cell-specific manner. Thus, simultaneous targeting of selected metabolic enzymes and “driving” oncogenes may be a cancer cell-selective therapeutic approach. As mentioned above, we discovered that USP2a binds to and stabilizes fatty acid synthase (FASN) by preventing its degradation (Graner et al Cancer Cell, 2004). This prompted us to initiate a research program focused on FASN. Specifically, investigated the expression of FASN in prostate cancer by immunohistochemistry as well as gene expression profiling demonstrating that it is overexpressed in aggressive prostate carcinomas (Rossi et al Mol Cancer Res 2003). Since FASN expression is highest in androgen-independent bone metastatic disease, we set out to determine whether it confers a growth advantage to prostate cancer. Using genetically engineered human prostate epithelial cells infected with FASN, transgenic mice expressing FASN in the murine prostate and well characterized human databases, we established that FASN can act as a prostate cancer oncogene in the presence of AR and that FASN exerts its oncogenic effect by inhibiting the intrinsic pathway of apoptosis (Migita et al J Natl Cancer Inst 2009). Subsequently, utilizing funds from an RO1 focused on AMPK and the metabolic syndrome in prostate cancer, we examined associations of five common SNPs within FASN with PCa incidence and PCa-specific death and tested for an interaction with body mass index (BMI). FASN germline polymorphisms were significantly associated with risk of lethal PCa. Significant interactions of BMI with FASN polymorphisms and FASN tumor expression suggest FASN as a potential link between obesity and poor PCa outcome and raise the possibility that FASN inhibition could reduce PCa-specific mortality, particularly in overweight men (Nguyen, J Clin Oncol, 2011). We recently expanded the analysis of metabolism in prostate cancer to assess the global metabolic profile by GS/MS in immortalized prostate epithelial cells and transgenic mice comparing Akt and Myc as the driving oncogenes. The results were then applied to human tumors previously categorized as to the status of these oncogenes. Results show starkly different metabolic profiles resulting from these oncogenes and signatures that could be applied to human tumors (Priolo, Cancer Res, 2014). Since drugs targeting FASN and radiotracers such as 11C acetate are now being utilized, these studies will undoubtedly have a significant clinical impact. Epidemiologic and biochemical studies have identified the energy sensor AMPK as an ideal target not only for metabolic diseases but also for cancer. In addition, biguanides such as metformin have cancer preventing/therapeutic properties. Utilizing a highly specific AMPK direct activator, we show that inhibition of de novo enhanced lipogenesis is the predominant downstream effector of AMPK-mediated inhibition over mTORC1 (EMBO Mol Med, 2014). We also derived a 123-gene signature that can be utilized to select patients that might benefit from either AMPK activators or inhibitors of lipid synthesis (manuscript submitted). We demonstrated that direct targeting of the metabolic hub, AMPK, represents a valid therapeutic strategy in prostate cancer. Selection of patients via a molecular signature of the “lipogenic phenotype” and subsequent monitoring of drug efficacy by noninvasive imaging with 11C-acetate as a lipid synthesis precursor provide the foundation for a novel therapeutic approach in prostate cancer. We recently showed that the inhibition of fatty acid synthesis arrested the cells at G2/M despite the presence of abundant fatty acids in the media. Our results suggest that de novo lipogenesis is essential for cell cycle completion. This “lipogenic checkpoint” at G2/M may be therapeutically exploited for hyperproliferative diseases such as cancer (Scaglia et all, Cell Cycle, 2014). Cell lineage in the prostate One of the major limitations in understanding the molecular events leading to prostate cancer is the fact that, in contrast to hematopoietic malignancies, the cell type undergoing transformation is unknown. In an effort to define cell lineages in prostate development, we have utilized p63 knock-out mice, in which we had previously reported prostate agenesis, and complemented it with tagged, p63 wild-type ES cells. Results demonstrate that secretory cells in the prostate derive from basal cells while superficial cells in the urothelium develop independently from p63-positive basal and intermediate cells (Signoretti et al, Proc Natl Acad Sci U S A, 2005). These findings have profound implications in the understanding of cell lineages in the prostate and, as a result, in the ultimate identification of the cell(s) of origin of prostatic adenocarcinomas. Molecular diagnostics I directed a Molecular Diagnostics laboratory in the early days of this field. As many as 30% of patients undergoing orthotopic liver transplantation did so for end-stage Hepatitis C (HCV) disease at the Deaconess Hospital in the 1990s. In order to diagnose HCV recurrence, and to differentiate it from rejection, we developed an RT-PCR method for detection of viruses in serum and liver tissues (Loda et al, Diag Molec Pathol 1996). This method was utilized clinically for several years at the Deaconess Hospital until kit-based tests became available. Cutaneous T cell lymphoproliferative disorders are often problematic to diagnose. We developed a PCR-based technique for the identification of T cell populations in paraffin-embedded tissue that are clonal and as such malignant (Signoretti et al Am J. 55 Loda - CV Pathol. 1999). Such a technique is easily performed, reproducible (identical clonal patterns can be recognized when recurrent lesions from the same patient are examined) and may be performed in laboratories with minimal molecular biology set ups. We have discovered that p63 is a specific marker of prostate basal cells and its absence could thus be used as a powerful biomarker of prostate cancer (Signoretti et al, Am J Pathol, 2000). This immunohistochemical test is now used by all diagnostic pathology laboratories around the world. Our group has obtained a patent for this discovery. In collaboration with Biogenex, Inc, San Ramon, CA, we have developed anti cdx2 monoclonal antibodies. This is now being used as a marker of colonic origin in metastatic adenocarcinomas of unknown primary (Barbareschi et al. Am J Surg Pathol 2003). We have licensed the antibody to Biogenex, Inc. Cdx2 immunohistochemistry has now become a routine test in most surgical pathology laboratories for the differential diagnosis of metastases from unknown primaries and for the identification of metaplastic epithelium (e.g. Barrett’s esophagus). More recently, we have perfected an ex vivo, reproducible, rapid and personalized culture method to investigate antitumoral pharmacological properties that preserves the original cancer microenvironment. Response to inhibitors in cancer is determined not only by properties of the drug target but also by mutations in other signaling molecules and the tumor microenvironment. My group in collaboration with Dr. Bosari’s group at the University of Milan, Italy, has shown that this culture model preserves tissue 3D architecture, cell viability, pathway activity, and global gene expression profiles up to 5 days ex vivo. In addition, we show pathway modulation in tumor cells resulting from pharmacologic intervention in ex vivo culture. This technology may have a significant impact on patient selection for clinical trials and in predicting response to small-molecule inhibitor therapy. (Vaira et al, Proc Natl Acad Sci U S A. 2010). Utilizing previously identified subsets of genes capable of providing a prognostic signature, my laboratory has developed a technique which entails hybridization of quantum dot-labeled oligonucleotides representing the signature genes to formalin-fixed, paraffin-embedded tissue microarrays, subsequent de-convolution of the multiplexed in situ hybridization signals by spectral imaging and analysis of the data via complex bioinformatics algorithms. Results from these studies (as well as other that utilized fluorescently-labeled antibodies) have paved the way for multiplexed molecular assessment of tumors in primary biopsy specimens that have recently been developed. Manuscripts on this area of research include Byers et al J Mol Diagn, 2007, Snyder et al Lab Invest, 2009 and Ding et al Nature. 2011. Teaching I have been actively involved in teaching of post-doctoral fellows, pathology residents and fellows as well as medical students since the start of my career. In the early stages of my career, I have been a tutor at Tufts University School of Medicine and a lecturer at the University of Bologna in Italy. I have been a laboratory leader and a tutor in the Pathology course at Harvard Medical School. I gave two yearly lectures to the students in the Division of Health Science and Technology HST (Combined Harvard/MIT human Pathology Course). I am the director of a course at the United States and Canadian Academy of Pathology (USCAP) entitled “Careers in investigative pathology: the road less traveled”. I am a member of the subcommittee on admission of students in the Faculty of Medicine, M.D. Ph.D. program, at Harvard Medical School. Since 2010 I have been the Director as well as lecturer of the Boot-Camp Course entitled “Molecular Pathology of Cancer” for the Harvard Graduate Ph.D. students. Clinical responsibilities Throughout my career I have always maintained a strong presence in the clinical arena, being involved in patient care at all times in all the academic institutions I have worked in. I have taken leadership roles as Director of clinical services such as diagnostic immunohistochemistry (Deaconess Hospital), diagnostic molecular pathology (Bellaria Hospital and Deaconess Hospital), the urologic pathology service (Brigham & Women’s Hospital) and the center for molecular oncologic pathology (Dana Farber Cancer Institute/ Brigham & Women’s Hospital). These roles have strong ties with both research (e.g. in the development of novel clinical tests which originated from the research performed in my laboratory - see for instance Loda et al, Diagn Molec Pathol 1996; 5: 81-87; Signoretti et al - Am J Pathol 2000; 157: 1769-75; Barbareschi et al. Am J Surg Pathol 2003 Feb;27(2):141-9) and teaching (e.g. training of residents rotating through the laboratory). I have directed the genito-urinary pathology diagnostic service and now continue to sign out diagnostic genitourinary pathology and molecular diagnostics at the Brigham and Women’s hospital. 56
![Genistein [446-72-0] - Università degli Studi di Roma "Tor Vergata"](http://s1.studyres.com/store/data/001069358_1-826841ed5b5b39775155b3058987503a-150x150.png)
